INVACARE (IVCRQ) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

DEI Document

DEI Document - shares	3 Months Ended
	Mar. 31, 2023	May 12, 2023	Dec. 31, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-15103
Entity Registrant Name	INVACARE HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-4264819
Entity Address, Address Line One	One Invacare Way,
Entity Address, City or Town	Elyria,
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44035
City Area Code	440
Local Phone Number	329-6000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,999,980
Entity Central Index Key	0000742112
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Preferred Stock, Shares Outstanding	0		0

Condensed Consolidated Statemen

Condensed Consolidated Statement of Comprehensive Income (Loss) - USD ($) shares in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net Sales		$ 165,481,000	$ 200,988,000
Cost of products sold		121,637,000	153,259,000
Gross Profit		43,844,000	47,729,000
Selling, general and administrative expenses		53,809,000	60,564,000
Net gain on sale of businesses		(4,212,000)	0
Charges related to restructuring activities		4,694,000	3,790,000
Operating Loss		(10,447,000)	(16,625,000)
Net gain on convertible debt derivatives		(85,000)	0
Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023)		9,101,000	6,252,000
Interest Income, Other		17,000	0
Loss Before Income Taxes		(40,237,000)	(22,877,000)
Income tax provision		940,000	1,320,000
Net Loss		$ (41,177,000)	$ (24,197,000)
Net Loss per Share—Basic
Net Loss per Share—Basic		$ (1.08)	$ (0.69)
Weighted Average Shares Outstanding—Basic		37,994	35,046
Net Loss per Share—Assuming Dilution
Net Loss per Share—Assuming Dilution	[1]	$ (1.08)	$ (0.69)
Net earnings (loss) per per common share—assuming dilution (in dollars per share)	[1]	$ (1.08)	$ (0.69)
Weighted Average Shares Outstanding—Assuming Dilution		38,037	35,419
Other comprehensive income (loss):
Foreign currency translation adjustments		$ 5,813,000	$ (6,342,000)
Defined benefit plans:
Amortization of prior service costs and unrecognized losses		30,000	224,000
Deferred tax adjustment resulting from defined benefit plan activity		(5,000)	(47,000)
Valuation reserve associated with defined benefit plan activity		5,000	47,000
Current period gain on cash flow hedges		0	880,000
Deferred tax provision related to gain on cash flow hedges		0	(56,000)
Other Comprehensive Income (Loss)		5,843,000	(5,294,000)
Comprehensive Loss		(35,334,000)	(29,491,000)
Reorganization Items		20,791,000	$ 0
Contractual Interest Expense on Prepetition Liabilities Not Recognized in Statement of Operations		$ 2,269,000
[1]Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Comprehensive Income (Loss) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Contractual Interest Expense on Prepetition Liabilities Not Recognized in Statement of Operations	$ 2,269

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 66,284	$ 58,792
Trade receivables, net	82,659	87,952
Installment receivables, net	263	311
Inventories, net	103,635	112,561
Other current assets	32,947	39,702
Total Current Assets	285,788	299,318
Other Assets	4,610	5,159
Intangibles, net	21,771	21,669
Property and Equipment, net	50,514	51,533
Finance Lease, Right-of-Use Asset	55,809	56,272
Operating Lease, Right-of-Use Asset	12,111	10,737
Goodwill	331,513	326,281
Total Assets	762,116	770,969
Current Liabilities
Accounts payable	72,588	104,590
Accrued expenses	77,712	106,091
Current taxes payable	2,636	2,774
Current portion of long-term debt	35,656	154
Current portion of finance lease obligations	3,162	3,106
Current portion of operating lease obligations	4,142	3,420
Total Current Liabilities	195,896	220,135
Long-Term Debt	137,241	354,087
Finance Lease Long-Term Obligations	57,808	57,994
Operating Leases Long-Term Obligations	7,956	7,259
Other Long-Term Obligations	29,650	50,402
Shareholders’ Equity
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	281,547	281,366
Retained earnings (accumulated deficit)	(119,603)	(78,426)
Accumulated other comprehensive income (loss)	(18,880)	(24,723)	$ 11,694	$ 16,988
Treasury Shares (4,536 and 4,536 shares at March 31, 2023 and December 31, 2022, respectively)	(107,939)	(107,939)
Total Shareholders’ Equity	45,939	81,092	$ 189,308	$ 218,489
Total Liabilities and Shareholders’ Equity	762,116	770,969
Common Shares [Member]
Shareholders’ Equity
Common Shares	10,812	10,812
Class B Common Shares [Member]
Shareholders’ Equity
Common Shares	$ 2	$ 2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	4,536	4,536
Cash and cash equivalents	$ 66,284	$ 58,792
Operating Leases Long-Term Obligations	7,956	7,259
Trade receivables, net	82,659	87,952
Installment receivables, net	263	311
Inventories, net	103,635	112,561
Other current assets	32,947	39,702
Assets, Current	285,788	299,318
Other Assets	4,610	5,159
Intangibles, net	21,771	21,669
Property and Equipment, net	50,514	51,533
Finance Lease, Right-of-Use Asset	55,809	56,272
Operating Lease, Right-of-Use Asset	12,111	10,737
Goodwill	331,513	326,281
Assets	762,116	770,969
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Liabilities and Equity	762,116	770,969
Accounts payable	72,588	104,590
Accrued expenses	77,712	106,091
Current taxes payable	2,636	2,774
Current portion of long-term debt	35,656	154
Current portion of finance lease obligations	3,162	3,106
Current portion of operating lease obligations	4,142	3,420
Liabilities, Current	195,896	220,135
Long-Term Debt	137,241	354,087
Finance Lease Long-Term Obligations	57,808	57,994
Other Long-Term Obligations	29,650	50,402
Treasury Stock, Value	107,939	107,939
Accumulated other comprehensive income (loss)	(18,880)	(24,723)
Retained earnings (accumulated deficit)	(119,603)	(78,426)
Additional paid-in-capital	281,547	281,366
Total Shareholders’ Equity	45,939	81,092
Liabilities Subject to Compromise	$ 287,626	$ 0
Common Shares [Member]
Common Stock, Shares Authorized	150,000	150,000
Common Stock, Shares, Issued	42,518	42,540
Common Shares	$ 10,812	$ 10,812
Class B Common Shares [Member]
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	4	4
Common Shares	$ 2	$ 2

Condensed Consolidated Statem_3

Condensed Consolidated Statement Of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Convertible Debt Discount Amortization and Accretion	$ 960,000	$ 911,000
Cash and cash equivalents		52,337,000
Effect of exchange rate changes on cash	413,000	(317,000)
Provision (benefit) for deferred income taxes	(38,000)	95,000
Other Noncash Expense	169,000	44,000
Provision for Doubtful Accounts	24,000	96,000
Net gain on convertible debt derivatives	85,000	0
Other Noncash Income	184,000	0
Noncash reorganization items net	5,464,000	0
Operating Activities
Net loss	(41,177,000)	(24,197,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Net gain on sale of businesses	(4,212,000)	0
Depreciation and amortization	3,570,000	3,942,000
Amortization of operating lease right of use assets	1,226,000	1,375,000
Provision for losses on trade and installment receivables	24,000	96,000
Provision (benefit) for deferred income taxes	(38,000)	95,000
Provision for equity compensation	181,000	310,000
Gain on disposals of property and equipment	(87,000)	(34,000)
Amortization of debt fees	1,817,000	615,000
Changes in operating assets and liabilities:
Trade receivables	5,605,000	10,481,000
Installment sales contracts, net	110,000	247,000
Inventories, net	2,980,000	(3,615,000)
Other current assets	6,976,000	(3,361,000)
Accounts payable	(3,201,000)	(8,323,000)
Accrued expenses	(10,765,000)	(4,372,000)
Other long-term liabilities	(315,000)	(1,824,000)
Net Cash Provided by (Used in) Operating Activities	30,614,000	(27,698,000)
Investing Activities
Purchases of property and equipment	(1,978,000)	(2,131,000)
Proceeds from sale of property and equipment	0	5,000
Proceeds from sale of businesses	11,596,000	0
Change in other long-term assets	2,000	(91,000)
Other	540,000	(4,000)
Net Cash Provided (Used) by Investing Activities	9,080,000	(2,213,000)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	43,042,000	3,484,000
Payments on revolving lines of credit and finance leases	(10,274,000)	(4,420,000)
Payment of financing costs (1)	(4,155,000)	(244,000)
Net Cash Provided (Used) by Financing Activities	28,613,000	(1,180,000)
Effect of exchange rate changes on cash	413,000	(317,000)
Cash, Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	7,492,000	(31,408,000)
Cash and cash equivalents at beginning of year	$ 58,792,000	83,745,000
Cash and cash equivalents at end of period		$ 52,337,000

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Shareholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Stock [Member] Class B Common Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]
Total Shareholders’ Equity at Dec. 31, 2021	$ 218,489	$ 9,977	$ 2	$ 276,665	$ 22,645	$ 16,988	$ (107,788)
Allocated Share-based Compensation Expense	(345)	0		(345)			0
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	655	0		655			0
Net Loss	(24,197)				(24,197)
Foreign currency translation adjustments	(6,342)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(6,342)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	824					824
Amortization of prior service costs and unrecognized losses	224
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	224
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(29,491)
Total Shareholders’ Equity at Mar. 31, 2022	189,308	9,977	2	276,975	(1,552)	11,694	(107,788)
Total Shareholders’ Equity at Dec. 31, 2022	81,092	10,812	2	281,366	(78,426)	(24,723)	(107,939)
Allocated Share-based Compensation Expense	(54)	0		(54)			0
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	235	0		235			0
Net Loss	(41,177)				(41,177)
Foreign currency translation adjustments	5,813
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	5,813
Amortization of prior service costs and unrecognized losses	30
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(35,334)
Total Shareholders’ Equity at Mar. 31, 2023	$ 45,939	$ 10,812	$ 2	$ 281,547	$ (119,603)	$ (18,880)	$ (107,939)

Divested Businesses (Notes)

Divested Businesses (Notes)	3 Months Ended
	Mar. 31, 2023
Divested Businesses [Abstract]
Divested Businesses	Divested Businesses On January 30, 2023, the company completed the sale of its respiratory business assets to Ventec Life Systems, Inc, a Delaware corporation and subsidiary of React Health, LLC (the “Purchaser”), pursuant to an Asset Purchase Agreement dated as of January 30, 2023 (the “Purchase Agreement”). The purchase price paid by the Purchaser was $11,925,644 in cash payable at closing. The Purchase Agreement contains customary indemnification obligations of each party with respect to breaches of their respective representations, warranties and covenants, and certain other specified matters, which are subject to certain exceptions, terms and limitations described further in the Purchase Agreement. The company agreed to non-competition obligations with respect to respiratory products for a five-year period following the Transaction, which are more fully described in the Purchase Agreement. In addition, the company entered into a supply agreement and a transition services agreement with the Purchaser to provide for, among other matters, the ongoing parts and service and support for the warranty and non-warranty service of respiratory products in the field. The foregoing description of the Purchase Agreement is a summary, does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement. On January 27, 2023, the company completed the sale of its Top End ® sports and recreational wheelchair and handcycle business net assets to Top End Sports, LLC. Cash proceeds on the sale were not material to the company. The net gain on the sale of these businesses was $4,212,000 for the three months ended March 31, 2023.

Receivables

Receivables	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Receivables	Receivables Receivables consist of the following (in thousands): March 31, 2023 December 31, 2022 Accounts receivable, gross $ 101,991 $ 112,659 Customer rebate reserve (7,853) (11,569) Cash discount reserves (7,042) (8,756) Allowance for doubtful accounts (3,143) (3,279) Other, principally returns and allowances reserves (1,294) (1,103) Accounts receivable, net $ 82,659 $ 87,952 Reserves for customer rebates and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principle as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company’s normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly. Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all the company’s receivables are due from healthcare, medical equipment providers and long-term care facilities predominantly located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, are ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The company's approach is to separate its receivables into good-standing and collection receivables. Good-standing receivables are assigned to risk pools of high, medium and low. The risk pools are driven by the specifics associated with the geography of origination. Expected loss percentages are calculated and assigned to each risk pool, driven primarily by historical experience. The historical loss percentages are calculated for each risk pool and then judgmentally revised to consider current risk factors as well as consideration of the impact of forecasted events, as applicable. The expected loss percentages are then applied to receivables balances each period to determine the allowance for doubtful accounts. In North America, excluding Canada, good-standing receivables are assigned to the low risk pool and assigned an expected loss percentage of 1.0% as these receivables are deemed to share the same risk profile and collections efforts are the same. Installment receivables in North America are characterized as collection receivables and thus reserves are based on specific analysis of each customer. In Canada, good-standing receivables are deemed low risk and assigned a loss percentage of 0.1%. In Europe, expected losses are determined by each location in each country. Most locations have a majority of their receivables assigned to the low risk pool, which has an average expected loss percentage of 0.3%. About half of the locations have a portion of their receivables assigned as medium risk with an average expected loss percentage of 0.8%. Only a few locations have any receivables characterized as high risk and the average credit loss percentage for those locations is 2.3%. Collection risk is generally low as payment terms in certain key markets, such as Germany, are immediate and in many locations the ultimate customer is the government. In the Asia Pacific region, receivables are characterized as low risk, which have an average expected loss percentage of 1.0%. Historical losses are low in this region where the use of credit insurance is often customary. The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended March 31, 2023 Balance as of beginning of period $ 3,279 Current period provision 24 Recoveries (direct write-offs), net (160) Balance as of end of period $ 3,143 The company did not make any material changes to the assignment of receivables to the different risk pools or to the expected loss reserves in the quarter. For collections receivables, the estimated allowance for uncollectible amounts is based primarily on management’s evaluation of the financial condition of each customer. In addition, as a result of the company's financing arrangement with DLL, a third-party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishes reserves for specific customers as needed. The company writes off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. Refer to Concentration of Credit Risk in the notes to the condensed consolidated financial statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the condensed consolidated balance sheets. The company has recorded a contingent liability in the amount of $286,000 related to the contingent aspect of the company's guarantee associated with its arrangement with DLL. The contingent liability is recorded applying the same expected loss model used for the trade and installment receivables recorded on the company's books. Specifically, historical loss history is used to determine the expected loss percentage, which is then adjusted judgmentally to consider other factors, as needed. The company’s U.S. customers electing to finance their purchases can do so using DLL. Repurchased DLL receivables recorded on the books of the company represent a single portfolio segment of receivables to the independent provider channel and long-term care customers. The portfolio segment of these receivables are distinguished by geography and credit quality. These receivables were repurchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The estimated allowance for uncollectible amounts and evaluation for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for most customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financial statements as well as consideration of other factors such as exposure to changing reimbursement laws. Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process for pursuing collection of outstanding amounts, the length of which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. Installment receivables consist of the following (in thousands): March 31, 2023 December 31, 2022 Current Long-Term Total Current Long-Term Total Installment receivables $ 263 $ 197 $ 460 $ 311 $ 266 $ 577 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 263 $ 197 $ 460 $ 311 $ 266 $ 577 No sales of installment receivables were made by the company during the quarter. Installment receivables by class as of March 31, 2023 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 460 460 — — Total installment receivables $ 460 $ 460 $ — $ — Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total installment receivables $ 577 $ 577 $ — $ — The aging of the company’s installment receivables was as follows (in thousands): March 31, 2023 December 31, 2022 Total Asia Pacific Total Asia Pacific Current $ 460 $ 460 $ 533 $ 533 0-30 days past due — — 44 44 31-60 days past due — — — — 61-90 days past due — — — — 90+ days past due — — — — $ 460 $ 460 $ 577 $ 577

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories, Net Inventories consist of the following (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 50,385 $ 45,476 Finished goods 44,263 57,174 Work in process 8,987 9,911 Inventories, net $ 103,635 $ 112,561

Other Current Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Other current assets consist of the following (in thousands): March 31, 2023 December 31, 2022 Tax receivables principally value added taxes $ 11,498 $ 22,946 Prepaid insurance 4,353 1,223 Prepaid inventory and freight 3,519 3,077 Service contracts 1,987 1,366 Receivable due from information technology provider 1,965 934 Recoverable income taxes 1,358 1,990 Derivatives (foreign currency forward exchange contracts) — 1,117 Deferred financing fees — 339 Prepaid and other current assets 8,267 6,710 Other Current Assets $ 32,947 $ 39,702 The receivable due from information technology provider is related to the Master Services Agreement with Birlasoft Solutions Inc. which was terminated on January 27, 2023 for breach of the agreement, including but not limited to Birlasoft's failure to meet transformation milestones, failure to provide services, and breach of representations, warranties and covenants in the Master Services Agreement. This receivable relates to the period prior to the bankruptcy filing. Collection of such receivable will be impacted by the outcome of the bankruptcy proceedings. Subsequent to quarter ended March 31, 2023, the company reached a settlement with Birlasoft Solutions Inc. which was approved by the Bankruptcy Court for a settlement payment of $2,000,000 by the company for disengagement services to be provided by Birlasoft and completed on or about May 31, 2023.

Other Long-Term Assets

Other Long-Term Assets	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets consist of the following (in thousands): March 31, 2023 December 31, 2022 Cash surrender value of life insurance policies $ 2,708 $ 2,686 Deferred income taxes 1,330 1,102 Installment receivables 197 266 Investments 87 85 Deferred financing fees — 733 Other 288 287 Other Long-Term Assets $ 4,610 $ 5,159

Property And Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property And Equipment	Property and Equipment Property and equipment consist of the following (in thousands): March 31, 2023 December 31, 2022 Machinery and equipment $ 264,629 $ 269,835 Capitalized software 30,921 30,923 Land, buildings and improvements 25,554 25,095 Furniture and fixtures 8,113 8,053 Leasehold improvements 4,684 4,802 Property and Equipment, gross 333,901 338,708 Accumulated depreciation (283,387) (287,175) Property and Equipment, net $ 50,514 $ 51,533

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The change in goodwill from December 31, 2022 to March 31, 2023 was due to foreign currency translation. In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill is tested annually for impairment or whenever events or changes in circumstances indicate the carrying value of a reporting unit could be above its fair value. A reporting unit is defined as an operating segment or one level below. The company has determined that its reporting units are North America, Europe and Asia Pacific. Assessment for impairment indicators for the first quarter of 2023 included considerations of the Chapter 11 Cases which were also assessed for the fourth quarter of 2022. Both assessments for the first quarter of 2023 and fourth quarter of 2022 concluded an updated quantitative assessment was not warranted. Refer to Goodwill in the company's Annual Report on Form 10-K for the period ending December 31, 2022 for further disclosure regarding the company's annual impairment assessment methodology.

Intangibles

Intangibles	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangibles	Intangibles The company's intangibles consist of the following (in thousands): March 31, 2023 December 31, 2022 Historical Accumulated Historical Accumulated Customer lists $ 49,129 $ 49,129 $ 48,515 $ 48,515 Trademarks 19,116 — 18,867 — Developed technology 7,231 6,973 7,154 6,859 Patents 4,088 4,088 4,092 4,092 License agreements 3,982 1,591 3,981 1,480 Other 1,148 1,142 1,148 1,142 Intangibles $ 84,694 $ 62,923 $ 83,757 $ 62,088 All of the company’s intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for trademarks shown above, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2022 to March 31, 2023 were primarily the result of foreign currency translation on historical cost and accumulated amortization as well as new license agreements. The company evaluates the carrying value of definite-lived assets whenever events or circumstances indicate possible impairment. Definite-lived assets are determined to be impaired if the future undiscounted cash flows expected to be generated by the asset are less than the carrying value. Actual impairment amounts for definite-lived assets are then calculated using a discounted cash flow calculation. The company evaluates the carrying value of indefinite-lived assets annually in the fourth quarter and whenever events or circumstances indicate possible impairment. Any impairment for indefinite-lived intangible assets is calculated as the difference between the future discounted cash flows expected to be generated by the asset and the carrying value of the asset. Amortization expense related to intangible assets was $153,000 in the first three months of 2023 and is expected to be $611,000 in 2023, $568,000 in 2024, $439,000 in 2025, $437,000 in 2026, $310,000 in 2027 and $212,000 in 2028. Amortized intangible assets are being amortized on a straight-line basis over remaining lives of 2 to 7 years with a weighted average remaining life of approximately 5.4 years.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of accruals for the following (in thousands): March 31, 2023 December 31, 2022 Salaries and wages $ 17,553 $ 19,307 Reorganization items, net 15,051 — Taxes other than income taxes, primarily value added taxes 12,084 27,106 IT service contracts 7,528 5,581 Warranty 7,026 7,981 Professional 6,616 11,267 Interest 6,359 6,900 Freight 4,324 4,542 Product line exit obligations 3,743 3,743 Product liability, current portion 2,344 2,125 Severance 1,979 3,472 Rebates 1,840 4,923 Deferred revenue 1,507 2,279 Insurance 770 951 Supplemental executive retirement program liability 391 391 Derivative liabilities (foreign currency forward exchange contracts) — 137 Other items, principally trade accruals 7,345 5,386 Accrued Expenses, prior to reclassification to Liabilities Subject to Compromise $ 96,460 $ 106,091 Less: Amounts reclassified to Liabilities Subject to Compromise 18,748 — Accrued Expenses $ 77,712 $ 106,091 Generally, the company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. The company has established procedures to appropriately defer such revenue. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as product field actions and recalls, which could require additional warranty reserve provisions. Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold. Rebates are netted against gross accounts receivables. If rebates are in excess of such receivables, they are then classified as accrued expenses. The reduction in accrued rebates from December 31, 2022 to March 31, 2023 primarily relates to payments principally made in the first quarter each year, earned from the previous year. The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2023 $ 7,981 Warranties provided during the period 396 Settlements made during the period (1,194) Changes in liability for pre-existing warranties during the period, including expirations (157) Balance as of March 31, 2023 $ 7,026

Other Long-Term Obligations

Other Long-Term Obligations	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Other Long-Term Obligations	Other Long-Term Obligations Other long-term obligations consist of the following (in thousands): March 31, 2023 December 31, 2022 Deferred income taxes $ 19,139 $ 18,771 Product liability 11,023 10,438 Deferred compensation 4,914 4,970 Deferred gain on sale leaseback 4,747 4,834 Supplemental executive retirement plan liability 4,413 4,383 Uncertain tax obligation including interest 2,918 2,891 Death benefit obligation plan 2,616 2,533 Pension 1,055 1,019 Secured Convertible 2026 debt conversion liability — 85 Other 388 478 Other Long-Term Obligations, prior to reclassification to Liabilities Subject to Compromise $ 51,213 $ 50,402 Less: Amounts reclassified to Liabilities Subject to Compromise 21,563 — Other Long-Term Obligations $ 29,650 $ 50,402 On April 23, 2015, the company entered into a real estate sale leaseback transaction which resulted in the company recording an initial deferred gain of $7,414,000, the majority of which is included in Other Long-Term Obligations and will be recognized over the 20-year life of the leases. The gain realized was $84,000 for the three months ended March 31, 2023, compared to $81,000 for the three months ended March 31, 2022.

Leases and Commitments (Notes)

Leases and Commitments (Notes)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Lessee, Finance Leases	Leases and Commitments Refer to the Subsequent Events note for discussion of changes (modifications and rejections) to certain real estate leases upon bankruptcy emergence on May 5, 2023. During the bankruptcy period through March 31, 2023, there were no modifications of Debtors leases. The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company combines lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of March 31, 2023, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the U.S. and Canadian Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then-current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the condensed consolidated balance sheets. In July of 2020, the company entered into a 19.75-year lease agreement in Germany. The lease increased the company's finance lease obligation by $38,704,000 and increased the finance lease expense compared to previous periods. Lease expenses for the three months ended March 31, 2023 and March 31, 2022, respectively, were as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Operating leases $ 1,548 $ 1,610 Variable and short-term leases 610 714 Total operating leases $ 2,158 $ 2,324 Finance lease interest cost $ 1,067 $ 1,083 Finance lease depreciation 1,067 1,092 Total finance leases $ 2,134 $ 2,175 Future minimum operating and finance lease commitments, as of March 31, 2023, are as follows (in thousands): Finance Operating Leases 2023 $ 5,151 $ 3,689 2024 6,808 3,894 2025 6,710 2,539 2026 6,599 1,224 2027 6,485 392 Thereafter 63,035 1,356 Total future minimum lease payments 94,788 13,094 Amounts representing interest (33,818) (996) Present value of minimum lease payments 60,970 12,098 Less: current maturities of lease obligations (3,162) (4,142) Long-term lease obligations $ 57,808 $ 7,956 Supplemental cash flow amounts for the three months ended March 31, 2023 and March 31, 2022 were as follows (in thousands): For the Three Months Ended March 31, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2023 2022 Operating leases $ 1,528 $ 2,239 Finance leases 1,843 1,829 Total $ 3,371 $ 4,068 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2023 2022 Operating leases $ 2,631 $ 716 Finance leases 5 175 Total $ 2,636 $ 891 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of March 31, 2023 and December 31, 2022, respectively: March 31, 2023 December 31, 2022 Weighted-average remaining lease term - finance leases 14.5 years 14.8 years Weighted-average remaining lease term - operating leases 4.1 years 4.6 years Weighted-average discount rate - finance leases 3.74% 3.74% Weighted-average discount rate - operating leases 15.36% 9.36%
Lessee, Operating Leases	Leases and Commitments Refer to the Subsequent Events note for discussion of changes (modifications and rejections) to certain real estate leases upon bankruptcy emergence on May 5, 2023. During the bankruptcy period through March 31, 2023, there were no modifications of Debtors leases. The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company combines lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of March 31, 2023, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the U.S. and Canadian Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then-current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the condensed consolidated balance sheets. In July of 2020, the company entered into a 19.75-year lease agreement in Germany. The lease increased the company's finance lease obligation by $38,704,000 and increased the finance lease expense compared to previous periods. Lease expenses for the three months ended March 31, 2023 and March 31, 2022, respectively, were as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Operating leases $ 1,548 $ 1,610 Variable and short-term leases 610 714 Total operating leases $ 2,158 $ 2,324 Finance lease interest cost $ 1,067 $ 1,083 Finance lease depreciation 1,067 1,092 Total finance leases $ 2,134 $ 2,175 Future minimum operating and finance lease commitments, as of March 31, 2023, are as follows (in thousands): Finance Operating Leases 2023 $ 5,151 $ 3,689 2024 6,808 3,894 2025 6,710 2,539 2026 6,599 1,224 2027 6,485 392 Thereafter 63,035 1,356 Total future minimum lease payments 94,788 13,094 Amounts representing interest (33,818) (996) Present value of minimum lease payments 60,970 12,098 Less: current maturities of lease obligations (3,162) (4,142) Long-term lease obligations $ 57,808 $ 7,956 Supplemental cash flow amounts for the three months ended March 31, 2023 and March 31, 2022 were as follows (in thousands): For the Three Months Ended March 31, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2023 2022 Operating leases $ 1,528 $ 2,239 Finance leases 1,843 1,829 Total $ 3,371 $ 4,068 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2023 2022 Operating leases $ 2,631 $ 716 Finance leases 5 175 Total $ 2,636 $ 891 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of March 31, 2023 and December 31, 2022, respectively: March 31, 2023 December 31, 2022 Weighted-average remaining lease term - finance leases 14.5 years 14.8 years Weighted-average remaining lease term - operating leases 4.1 years 4.6 years Weighted-average discount rate - finance leases 3.74% 3.74% Weighted-average discount rate - operating leases 15.36% 9.36%

Revenue Revenue

Revenue Revenue	3 Months Ended
	Mar. 31, 2023
Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue The company has two revenue streams: products and services. Services include repair, refurbishment, preventive maintenance and rental of products. Services for the North America segment include maintenance and repair of products. Services for the Europe segment include repair, refurbishment and preventive maintenance services. Services in All Other, are in the Asia Pacific region, and include rental and repair of products. The following tables disaggregate the company’s revenues by major source and by reportable segment for the three months ended March 31, 2023 and March 31, 2022 (in thousands): Three Months Ended March 31, 2023 Product Service Total Europe $ 101,874 $ 3,049 $ 104,923 North America 51,906 458 52,364 All Other 6,876 1,318 8,194 Total $ 160,656 $ 4,825 $ 165,481 % Split 97% 3% 100% Three Months Ended March 31, 2022 Product Service Total Europe $ 115,265 $ 2,814 $ 118,079 North America 75,183 136 75,319 All Other 6,382 1,208 7,590 Total $ 196,830 $ 4,158 $ 200,988 % Split 98% 2% 100% The company's revenues are principally related to the sale of products, approximately 97%, with the remaining 3% related to services including repair, refurbishment, preventive maintenance and rental of products. While the company has a significant amount of contract types, the sales split by contract type is estimated as follows: general terms and conditions (25%), large national customers (20%), governments, principally pursuant to tender contracts (23%) and other customers including buying groups and independent customers (32%). All product revenues and substantially all service revenues are recognized at a point in time. The remaining service revenue, recognized over time, are reflected in the Europe segment and include multiple performance obligations. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price. The company generally determines the standalone selling price based on the expected cost-plus margin methodology. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company’s products and services. The amount of consideration received and revenue recognized by the company can vary as a result of variable consideration terms included in the contracts related to customer rebates, cash discounts and return policies. Revenue is measured as the amount of consideration probable of not having a significant reversal of cumulative revenue recognized when related uncertainties are resolved. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. In addition, customers have the right to return products within the company’s normal terms policy, and as such the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration it expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (refer to “Receivables” and "Accrued Expenses" in the notes to the condensed consolidated financial statements included elsewhere in this report for more detail).

Equity Compensation

Equity Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Shareholders' Equity Transactions	Equity Compensation The company’s common shares have a $0.25 stated value. The common shares and the Class B common shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B common shares have ten votes per share and, in general, can only be transferred to family members or for estate planning purposes. Holders of Class B common shares are entitled to convert their shares into common shares at any time on a share-for-share basis. When Class B common shares are transferred out of a familial relationship, they automatically convert to common shares. As of March 31, 2023, 3,667 Class B common shares remained outstanding. Prior conversions of Class B common shares have virtually eliminated the company’s dual-class voting structure. As of March 31, 2023, the holders of the common shares represented approximately 99.9% of the company’s total outstanding voting power. Equity Compensation Plan On May 17, 2018, the shareholders of the company approved the Invacare Corporation 2018 Equity Compensation Plan (the “2018 Plan”), which was adopted on March 27, 2018 by the company's Board of Directors (the “Board”). The company’s Board adopted the 2018 Plan in order to authorize additional common shares for grant as equity compensation and to reflect changes to Section 162(m) of the Internal Revenue Code (the “Code”) resulting from the U.S. Tax Cuts and Jobs Act of 2017. Following shareholder approval of the 2018 Plan, all of the common shares then-remaining available for issuance under the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”) and all of the common shares that were forfeited or remained unpurchased or undistributed upon termination or expiration of awards under the 2013 Plan and under the Invacare Corporation 2003 Performance Plan (the “2003 Plan”), become available for issuance under the 2018 Plan. Awards granted previously under the 2013 Plan and 2003 Plan will remain in effect under their original terms. The 2018 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any common shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each common share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share. The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2018 Plan to any director or employee of the company or an affiliate. As of March 31, 2023, 5,329,514 common shares were available for future issuance under the 2018 Plan in connection with the following types of awards with respect to the company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Compensation Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. The 2018 Plan provides that shares granted come from the company's authorized but unissued common shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares. The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Restricted stock and restricted stock units $ 235 $ 655 Performance shares and performance share units (54) (345) Total stock-based compensation expense $ 181 $ 310 As of March 31, 2023, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan, which is related to non-vested awards, was as follows (in thousands): March 31, 2023 Restricted stock and restricted stock units $ 1,836 Performance shares and performance share units 2 Total unrecognized stock-based compensation expense $ 1,838 Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (refer to "Stock Options" and "Performance Shares and Performance Share Units" below). No tax benefits for stock compensation were realized during the three months ended March 31, 2023 and 2022, respectively, due to a valuation allowance against deferred tax assets. In accordance with ASC 718, any tax benefits resulting from tax deductions in excess of the compensation expense recognized are classified as a component of financing cash flows. Stock Options Generally, non-qualified stock option awards have a term of ten years and were granted with an exercise price per share equal to the fair market value of the company’s common shares on the date of grant. The following table summarizes information about stock option activity for the three months ended March 31, 2023: 2023 Weighted Average Options outstanding at January 1, 2023 189,689 $ 13.43 Forfeited (103,462) 14.49 Options outstanding at March 31, 2023 86,227 $ 12.15 Options exercise price range at March 31, 2023 $ 12.15 to $ 12.15 Options exercisable at March 31, 2023 86,227 Shares available for grant under the 2018 Plan at March 31, 2023* 5,329,514 ________ * Shares available for grant under the 2018 Plan as of March 31, 2023 are reduced by awards and increased by forfeitures or expirations. At March 31, 2023, an aggregate of 1,466,569 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer. The following table summarizes information about stock options outstanding at March 31, 2023: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Exercisable at Weighted Average $12.15 – $20.00 86,227 3.96 $ 12.15 86,227 $ 12.15 The 2018 Plan provides for a one-year minimum vesting period for stock options and, generally, options must be exercised within ten years from the date granted. No stock options were issued in 2023 or 2022. Restricted Stock and Restricted Stock Units The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): 2023 Weighted Average Fair Value Stock / Units unvested at January 1, 2023 1,061,867 $ 2.75 Forfeited (23,601) 3.35 Stock / Units unvested at 1,038,266 $ 2.73 The restricted awards generally vest ratably over the three years after the award date. Unearned restricted awards compensation, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period as adjusted for forfeiture estimates. Performance Shares and Performance Share Units The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): 2023 Weighted Average Fair Value Shares / Units unvested at January 1, 2023 318,071 $ 5.15 Shares / Units unvested at 318,071 $ 5.15 During the three months ended March 31, 2023, no performance shares or performance share units (for non-U.S. recipients) were granted. Performance awards have a three year performance period with payouts based on achievement of certain performance goals. The awards are classified as equity awards as they will be settled in common shares upon vesting. The number of shares earned will be determined at the end of the three year performance period based on achievement of performance criteria for January 1, 2021 through December 31, 2023 and January 1, 2022 through December 31, 2024, respectively established by the Compensation Committee at the time of grant. Recipients will be entitled to receive a number of common shares equal to the number of performance shares that vest based upon the levels of achievement which may range between 0% and 150% of

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) by Component	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) by Component	Accumulated Other Comprehensive Income (Loss) by Component Changes in accumulated other comprehensive income (loss) ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2022 $ (23,879) $ (3,230) $ 2,386 $ — $ (24,723) OCI before reclassifications 6,283 (470) (77) (93) 5,643 Amount reclassified from accumulated OCI — — 107 93 200 Net current-period OCI 6,283 (470) 30 — 5,843 March 31, 2023 $ (17,596) $ (3,700) $ 2,416 $ — $ (18,880) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (6,768) 426 318 875 (5,149) Amount reclassified from accumulated OCI — — (94) (51) (145) Net current-period OCI (6,768) 426 224 824 (5,294) March 31, 2022 $ 12,193 $ 2,553 $ (3,877) $ 825 $ 11,694 Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended March 31, 2023 2022 Defined Benefit Plans Service and interest costs $ 107 $ (94) Selling, general and administrative expenses Tax — — Income taxes Total after tax $ 107 $ (94) Derivatives Foreign currency forward contracts hedging sales $ — $ (27) Net sales Foreign currency forward contracts hedging purchases 133 (31) Cost of products sold Total loss (income) before tax 133 (58) Tax (40) 7 Income taxes Total after tax $ 93 $ (51)

Charges Related To Restructurin

Charges Related To Restructuring Activities	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Charges Related To Restructuring Activities	Charges Related to Restructuring Activities The company's restructuring charges were originally necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affected the company's customers (e.g. home healthcare providers) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations. Restructuring decisions were also the result of reduced profitability in each of the segments. Restructuring actions have continued into 2023. For the three months ended March 31, 2023, charges totaled $4,694,000 which were related to North America of $3,722,000 and Europe of $972,000. Charges were related to severance costs and other restructuring costs (primarily advisory professional fees). Payments for the three months ended March 31, 2023 were $10,706,000 and the cash payments were funded with the company's cash on hand. The 2023 charges are expected to be paid out within 12 months. For the three months ended March 31, 2022, severance and other charges totaled $3,790,000 which were related to North America of $1,662,000, Europe of $2,119,000 and All Other of $9,000. Payments for the three months ended March 31, 2022 were $1,336,000 and the cash payments were funded with the company's cash on hand. There have been no material changes in accrued balances related to the charges, either as a result of revisions to the plans or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. A progression by reporting segment of the accruals recorded as a result of the restructuring for the three months ended March 31, 2023 is as follows (in thousands): Severance Contract Terminations Other Total December 31, 2022 Balances North America $ 967 $ — $ 3,026 $ 3,993 Europe 1,314 — 1,493 2,807 All Other 1,191 — — 1,191 Total 3,472 — 4,519 7,991 Charges North America 57 — 3,665 3,722 Europe 78 654 240 972 All Other — — — — Total 135 654 3,905 4,694 Payments North America (591) — (6,691) (7,282) Europe (849) (654) (1,733) (3,236) All Other (188) — — (188) Total (1,628) (654) (8,424) (10,706) March 31, 2023 Balances North America 433 — — 433 Europe 543 — — 543 All Other 1,003 — — 1,003 Total $ 1,979 $ — $ — $ 1,979

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The company had an effective tax rate of 2.3% and 5.8% on losses before tax for the three months ended March 31, 2023 and March 31, 2022, respectively, compared to a statutory benefit of 21.0% on the pre-tax loss for each period. The company's effective tax rate for the three months ended March 31, 2023 and March 31, 2022 was unfavorable as compared to the U.S. federal statutory rate, principally due to the negative impact of the company's inability to record tax benefits related to the significant losses in countries which had tax valuation allowances. The effective tax rate was increased for the three months ended March 31, 2023 and March 31, 2022 by certain taxes outside the United States, excluding countries with tax valuation allowances, that were at an effective rate higher than the U.S. statutory rate.

Net Earnings (Loss) Per Common

Net Earnings (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Common Share	Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended March 31, 2023 2022 Basic Weighted average common shares outstanding 37,994 35,046 Net loss $ (41,177) $ (24,197) Net loss per common share $ (1.08) $ (0.69) Diluted Weighted average common shares outstanding 37,994 35,046 Share options and awards 43 373 Weighted average common shares assuming dilution 38,037 35,419 Net loss $ (41,177) $ (24,197) Net loss per common share * $ (1.08) $ (0.69) ________ * Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss. For the three ended March 31, 2023, shares associated with equity compensation awards of 1,246,025 and for the three months ended March 31, 2022, shares associated with equity compensation awards of 1,861,644 were excluded from the weighted average common shares assuming dilution as incremental shares were antidilutive. At March 31, 2023, the majority of the antidilutive incremental shares were awards granted at an exercise price above $12.15, which was higher than the average fair market value price of $0.23. At March 31, 2022, the majority of the antidilutive incremental shares were awards granted at an exercise price above $12.15, which was higher than the average fair market value price of $2.14. For the three months ended March 31, 2023 and March 31, 2022, respectively, no shares were included in the common shares assuming dilution related to the company's issued warrants as the average market price of the company shares for these periods did not exceed the strike price of the warrants. Upon adoption of ASU 2020-06, effective in 2021 for the company, use of the if-converted earnings per share method is required. However, no shares were included in the weighted average common shares assuming dilution for the three months ended March 31, 2023 and March 31, 2022

Concentration Of Credit Risk

Concentration Of Credit Risk	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Concentration Of Credit Risk	Concentration of Credit Risk The company manufactures and distributes durable medical equipment to the home healthcare, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third-party financing company, to provide lease financing to Invacare's U.S. customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation of $2,113,000 at March 31, 2023 to DLL for events of default under the contracts, which total $6,941,000 at March 31, 2023. Guarantees, ASC 460, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded an immaterial liability for this guarantee obligation within other long-term obligations. The company's recourse is reevaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables purchased by the company from DLL. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4 . Credit losses are provided for in the financial statements. Substantially all the company’s receivables are due from healthcare, medical equipment providers and long-term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe or also direct from governmental entities in certain countries. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. Changes in these programs can have a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home healthcare industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers.

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives ASC 815 requires companies to recognize all derivative instruments in the condensed consolidated balance sheets as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. Cash Flow Hedging Strategy The company uses derivative instruments in an attempt to manage its exposure to transactional foreign currency exchange risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. The company recognizes its derivative instruments as assets or liabilities in the condensed consolidated balance sheets measured at fair value. All of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the condensed consolidated statements of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 50% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, most of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $6,720,000 and $10,666,000 matured during the three months ended March 31, 2023 and March 31, 2022. At March 31, 2023 and December 31, 2022, there were no outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment. Derivatives Not Qualifying or Designated for Hedge Accounting Treatment The company utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the company in 2023 or 2022 related to these contracts and the associated short-term intercompany trading receivables and payables. Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2023 and 2022, respectively, and outstanding were as follows (in thousands USD): March 31, 2023 December 31, 2022 Notional Gain Notional Gain USD / EUR — — 60,964 980 $ — $ — $ 60,964 $ 980 The fair values of the company’s derivative instruments were as follows (in thousands): March 31, 2023 December 31, 2022 Assets Liabilities Assets Liabilities Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts — — 1,117 137 Total derivatives $ — $ — $ 1,117 $ 137 The fair values of the company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the condensed consolidated balance sheets. The effect of derivative instruments on Accumulated Other Comprehensive Income (Loss) (OCI) and the condensed consolidated Statements of comprehensive income (loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended March 31, 2023 Foreign currency forward exchange contracts $ (93) $ (93) $ — Three months ended March 31, 2022 Foreign currency forward exchange contracts $ 875 $ 51 $ — Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended March 31, 2022 Foreign currency forward exchange contracts $ 602 The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales and in cost of products sold for hedges of inventory purchases. For the three months ended March 31, 2023, net sales were decreased by $0 while cost of products sold was increased by $133,000 for net pre-tax realized loss of $133,000. For the three months ended March 31, 2022, net sales were increased by $27,000 while cost of products sold was decreased by $31,000 for net realized pre-tax gain of $58,000. No gain or loss was recognized in selling, general and administrative (SG&A) expenses for the three months ended March 31, 2023 compared to a gain of $602,000 for the three months ended March 31, 2022 related to forward contracts not designated as hedging instruments. The forward contracts were entered into to offset gains/losses that were also recorded in SG&A expenses on intercompany trade receivables or payables. The gains/losses on the non-designated hedging instruments were substantially offset by gains/losses on intercompany trade payables. The company's derivative agreements provide the counterparties with a right of set off in the event of a default. The right of set off would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Prior Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Prior Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. As a result of the Debtors filing for bankruptcy, any outstanding cash flow hedges were required to be settled and the company is not able to enter into such transactions while in Bankruptcy. During 2022, the company entered into privately negotiated Secured Convertible 2026 Notes of $41,475,000 in aggregate principal amount. Convertible debt conversion liabilities of $1,595,000 were recorded based on initial fair values and these fair values are updated quarterly with the offset to the income statement. Refer to “Long-Term Debt” in the notes to the consolidated financial statements for more detail. The fair values of the outstanding convertible note derivatives as of March 31, 2023 and their effect on the Statement of Comprehensive Income (Loss) were as follows (in thousands): Fair Value Gain Secured Convertible 2026 Notes conversion long-term liability $ — $ 85

Fair Values

Fair Values	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Values Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III December 31, 2022 Forward exchange contracts—net — $ 980 — Secured convertible 2026 debt conversion liability — $ (85) — The carrying values and fair values of the company’s financial instruments are as follows (in thousands): March 31, 2023 December 31, 2022 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 66,284 $ 66,284 $ 58,792 $ 58,792 Forward contracts in Other current assets — — 1,117 1,117 Forward contracts in Accrued expenses — — (137) (137) Total debt (including current maturities of long-term debt) * (393,264) (170,940) (354,241) (278,027) Series I 2024 Notes (72,909) (3,645) (72,408) (62,460) Series II 2024 Notes (77,758) (3,888) (76,719) (64,678) 2026 Notes (69,700) (3,485) (67,665) (32,276) 2026 Secured Notes (37,404) (27,529) (37,240) (34,341) 2026 Term Loan (50,954) (47,854) (82,808) (66,871) DIP Term Loan (68,499) (68,499) — — Other (16,040) (16,040) (17,401) (17,401) Secured convertible 2026 debt conversion liability in Other Long-Term Obligations — — (85) (85) ________ * The company's total debt is shown net of discount and fees on the company's condensed consolidated balance sheets. Accordingly, the fair values included in the long-term debt presented in this table are also shown net of discount and fees. Total debt amounts exclude operating and finance lease obligations. The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value. The fair values are deemed to be categorized as Level 1. Forward Contracts: The company operates internationally, and as a result, is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third-party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, DKK, EUR, GBP, MXN, NOK, NZD, SEK, THB, and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities. The fair values are deemed to be categorized as Level 2. The company's forward contracts are included in Other Current Assets or Accrued Expenses in the condensed consolidated balance sheets. Total debt: Fair value for the company’s convertible debt at December 31, 2022, other than the 2026 Secured Notes and Term Loan, is based on quoted market-based estimates as of the end of the period. For the company's unsecured convertible debt at March 31, 2023, fair values align with the general unsecured creditor estimations presented to the Bankruptcy Court on March 29, 2023. The fair values are deemed to be categorized as Level 2 in the fair value hierarchy. The 2026 Secured Notes and Term Loan fair values are based on valuation models in which significant inputs are observable in active markets. The fair values are deemed to be categorized as Level 2. The DIP Term Loan is short term in nature where the gross carrying value reported in the balance approximates its fair value. Other total debt is primarily attributable to revolving credit facilities borrowings where the carrying value reported in the balance approximates its fair value due to the variable rates approximating market and the short term nature of the DIP ABL. Convertible debt derivative: The fair value for the convertible debt conversion liability is based on valuation models in which significant inputs are observable in active markets. The fair values are deemed to be categorized as Level 2.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Business Segments	Business Segments The company operates in two primary business segments: North America and Europe with each selling the company's primary product categories, which include: lifestyle, mobility and seating and respiratory therapy products. Sales in Asia Pacific are reported in All Other and include products similar to those sold in North America and Europe. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company's condensed consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Segment performance is measured and resources are allocated based on a number of factors, with the primary income or loss measure being segment operating income (loss). Segment operating income (loss) represents net sales less cost of products sold less selling general and administrative expenses. Segment operating income (loss) excludes unallocated corporate general and administrative expenses not allocated to the segments and intersegment sales and profit eliminations, which are included in All Other. In addition, segment operating income (loss) further excludes charges related to restructuring activities, asset impairment and gain on sale of business (as applicable). This performance measure, segment operating income (loss), is used by the Chief Operating Decision Maker (CODM) for purposes of making decisions about allocating resources to a segment and assessing its performance. In addition, this metric is reviewed by the company's Board of Directors regarding segment performance and is a key metric in the performance management assessment of the company's employees. The information by segment is as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Revenues from external customers Europe $ 104,923 $ 118,079 North America 52,364 75,319 All Other (Asia Pacific) 8,194 7,590 Consolidated $ 165,481 $ 200,988 Intersegment revenues Europe $ 4,431 $ 4,435 North America 6,842 11,096 All Other (Asia Pacific) 10 — Consolidated $ 11,283 $ 15,531 Restructuring charges before income taxes Europe $ 972 $ 2,119 North America 3,722 1,662 All Other — 9 Consolidated $ 4,694 $ 3,790 Operating income (loss) Europe $ 6,170 $ 3,225 North America (10,315) (8,336) All Other (5,820) (7,724) Charges related to restructuring activities (4,694) (3,790) Net gain on sale of businesses 4,212 — Consolidated operating loss (10,447) (16,625) Net gain on convertible debt derivatives 85 — Net interest expense (9,084) (6,252) Reorganization items, net (20,791) — Loss before income taxes $ (40,237) $ (22,877) Net sales by product, are as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Europe Lifestyle $ 52,802 $ 61,064 Mobility and Seating 42,916 47,402 Respiratory Therapy 4,692 4,663 Other(1) 4,513 4,950 $ 104,923 $ 118,079 North America Lifestyle $ 28,049 $ 34,301 Mobility and Seating 22,312 25,422 Respiratory Therapy 1,545 15,460 Other(1) 458 136 $ 52,364 $ 75,319 All Other (Asia Pacific) Mobility and Seating $ 2,384 $ 2,690 Lifestyle 2,758 2,826 Respiratory Therapy 1,639 779 Other(1) 1,413 1,295 $ 8,194 $ 7,590 Total Consolidated $ 165,481 $ 200,988 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies General In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All the product liability lawsuits that were asserted against the company in the United States prior to January 31, 2023 had been referred to the company's captive insurance company ("Invatection Insurance Company"), and/or excess insurance carriers. All non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. On January 31, 2023, the company entered into a Commutation and Release Agreement with Invatection pursuant to which, among other things, the company assumed all outstanding insured claims and cancelled the captive insurance policy. On March 28, 2023, Invatection was dissolved. The company self-insures product liability claims for the first $10 million per claim beyond which the company has commercial excess liability insurance coverage. The product liability lawsuits and claims arising prior to January 31, 2023, will be compromised pursuant to the company’s plan of reorganization under the Bankruptcy Cases. As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting, developing, testing, manufacturing, labeling, promoting, distributing and other practices of healthcare suppliers and medical device manufacturers are all subject to government scrutiny. Most of the company's facilities are subject to inspection at any time by the FDA or similar medical device regulatory agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could have a material adverse effect on the company's business. Medical Device Regulatory Matters The FDA in the United States and comparable medical device regulatory authorities in other jurisdictions regulate virtually all aspects of the marketing, invoicing, documenting, development, testing, manufacturing, labeling, promotion, distribution and other practices regarding medical devices. The company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the company's products are manufactured or sold. The company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions or enforcement actions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production. In December 2012, the company became subject to a consent decree of injunction filed by the FDA with respect to the company's Corporate facility and its Taylor Street manufacturing facility in Elyria, Ohio. The consent decree initially limited the company's (i) manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility ("Taylor Street products") , except in verified cases of medical necessity, (ii) design activities related to wheelchairs and power beds that take place at the impacted Elyria facilities and (iii) replacement, service and repair of products already in use from the Taylor Street manufacturing facility. Under the terms of the consent decree, in order to resume full operations, the company had to successfully complete independent, third-party expert certification audits at the impacted Elyria facilities, comprising three distinct certification reports separately submitted to, and subject to acceptance by, the FDA; submit its own report to the FDA; and successfully complete a reinspection by the FDA of the company's Corporate and Taylor Street facilities. On July 24, 2017, following its June 2017 reinspection of the Corporate and Taylor Street facilities, the FDA notified the company that it was in substantial compliance with the Federal Food, Drug and Cosmetic Act ("FDA Act"), FDA regulations and the terms of the consent decree and, that the company was permitted to resume full operations at those facilities including the resumption of unrestricted sales of products made in those facilities. Since July 24, 2017, an independent company-retained audit firm conducted two semi-annual audits in the first year and then four annual audits in the next four years of the company's headquarters and Taylor Street facilities, as required under the consent decree. The expert audit firm determined that the facilities remained in continuous compliance with the FDA Act, FDA regulations and the terms of the consent decree and issued post-audit reports contemporaneously to the FDA. The FDA has the authority to inspect these facilities and any other FDA registered facility, at any time. The FDA has continued to actively inspect the company's facilities, other than through the processes established under the consent decree. The company expects that the FDA will, from time to time, inspect substantially all the company's domestic and foreign FDA-registered facilities. In 2021, FDA conducted an inspection of the company’s Corporate and Taylor Street facilities and at the close of the inspection on June 24, 2021, issued its FDA Form 483 with six observations. The company timely responded to the FDA and has diligently taken actions to address FDA’s inspectional observations. On November 18, 2021, the company received a warning letter from the FDA concerning certain of the inspectional observations in the June 2021 FDA Form 483 related to the complaint handling process, the corrective and preventive action (“CAPA”) process, and medical device reporting (“MDR”) associated with oxygen concentrators (the “Warning Letter”). On November 16, 2021, the company received a consent decree non-compliance letter from the FDA concerning the same complaint and CAPA handling matters as in the Warning Letter observations but associated with the Taylor Street products (this letter, together with the Warning Letter, the “FDA Letters”). The company timely responded to the FDA Letters, has diligently taken actions to address the FDA’s concerns, and has provided the FDA with periodic updates on the corrective actions taken to address the matters in the FDA Letters. The FDA conducted an inspection at the company’s Corporate and Taylor Street facilities from March 1 through March 30, 2023. At the conclusion of the inspection, two FDA Form 483 observations were issued. The company timely responded to FDA and intends to diligently address the observations. The company remains committed to resolving the FDA’s concerns; however, it is not possible to predict the outcome or timing of a resolution at this time. There can be no assurance that the FDA will be satisfied with the company’s responses to the FDA Letters and Form 483, nor any assurance as to the timeframe that may be required for the company to adequately address the FDA’s concerns or whether the matters in the FDA Letters and Form 483 will result in an extension in the duration of the consent decree. As of the date of filing of the company’s Quarterly Report on Form 10-Q, there has been no impact on the company’s ability to produce and market its products as a result of the FDA Letters or the Form 483. Under the consent decree, the FDA has the authority to order the company to take a wide variety of actions if the FDA finds that the company is not in compliance with the consent decree, FDA Act or FDA regulations, including requiring the company to cease all operations relating to Taylor Street products. The FDA also can order the company to undertake a partial cessation of operations or a recall, issue a safety alert, public health advisory, or press release, or to take any other corrective action the FDA deems necessary with respect to Taylor Street products. The FDA also has authority under the consent decree to assess liquidated damages of $15,000 per violation per day for any violations of the consent decree, FDA regulations or the FDA Act. The FDA also may assess liquidated damages for shipments of adulterated or misbranded devices in the amount of twice the sale price of any such adulterated or misbranded device. The liquidated damages, if assessed, are limited to a total of $7,000,000 for each calendar year. The authority to assess liquidated damages is in addition to any other remedies otherwise available to the FDA, including civil money penalties. The results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA Letters, any other FDA warning letters or inspectional observations, or other FDA enforcement related to company facilities, could materially and adversely affect the company's business, financial condition, and results of operations. The limitations previously imposed by the FDA consent decree negatively affected net sales in the North America segment and, to a certain extent, the Asia Pacific region beginning in 2012. The limitations led to delays in new product introductions. Further, uncertainty regarding how long the limitations would be in effect limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. Although the company has been permitted to resume full operations at the Corporate and Taylor Street facilities, the negative effect of the consent decree on customer orders and net sales in the North America segment and Asia Pacific region has been considerable, and it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the company's historic results, the previous limitations in the consent decree had, and likely may continue to have, a material adverse effect on the company's business, financial condition and results of operations. Warranty Matters The company's warranty reserves are subject to adjustment in future periods based on historical analysis of warranty claims and as new developments occur that may change the company's estimates related to specific product recalls. Refer to Current Liabilities in the notes to the condensed consolidated financial statements for the total provision amounts and a reconciliation of the changes in the warranty accrual. Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations. For additional information regarding the consent decree, other regulatory matters, and risks and trends that may impact the company’s financial condition or results of operations, please see the following sections of the company's Annual Report on Form 10-K for the year ended December 31, 2022: Item 1. Business - Government Regulation and Item 1A. Risk Factors; Item 3. Legal Proceedings; and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.

Reorganizations

Reorganizations	3 Months Ended
	Mar. 31, 2023
Reorganizations [Abstract]
Liabilities subject to compromise disclosure	Liabilities Subject to Compromise During the Chapter 11 Cases, the company operated as debtor-in-possession under the jurisdiction of the Bankruptcy Court and in accordance with provisions of the Bankruptcy Code. On the accompanying Condensed Consolidated Balance Sheet, the caption “Liabilities Subject to Compromise” reflects the expected allowed amount of the pre-petition claims that are not fully secured and that have at least a possibility of not being repaid at the full claim amount. Liabilities Subject to Compromise at March 31, 2023 consisted of the following (in thousands): March 31, 2023 Current liabilities Accounts payable $ 26,948 Accrued expenses 18,748 Total current liabilities 45,696 Long-term debt 220,367 Other long-term obligations 21,563 Total Liabilities Subject to Compromise $ 287,626 Determination of the value at which liabilities will ultimately be settled cannot be made until the Bankruptcy Court approves the Plan and reconciliation of claims occurs. The company will continue to evaluate the amount and classification of its pre-petition liabilities. Any additional liabilities that are subject to compromise will be recognized accordingly, and the aggregate amount of Liabilities Subject to Compromise may change.
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure	Reorganization Items, Net Reorganization items incurred as a result of the Chapter 11 Cases are presented separately in the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2023 and consist of the following (in thousands): For the Three Months Ended March 31, 2023 Professional fees $ 13,598 DIP financing costs 5,474 Write-off of pre-petition debt issuance costs 4,060 Gain on settlements of pre-petition claims (2,341) Reorganization items, net $ 20,791 Professional fees included in Reorganization items, net represent fees for post-petition expenses related to the Chapter 11 Cases. As of March 31, 2023, $15,051,000 of professional fees and DIP financing costs were unpaid and accrued in Accrued Expenses in the Condensed Consolidated Balance Sheet. Cash paid for reorganization items, net was $4,021,000 for the three months ended March 31, 2023. Payments consisted of $3,664,000 for DIP financing costs reflected in the Financing Activities section of the Condensed Consolidated Statements of Cash Flows, and $357,000 of professional fees reflected in the Operating Activities section of the Condensed Consolidated Statements of Cash Flows. The write-off of pre-petition debt issuance costs and gain on settlements of pre-petition claims are included on the Reorganization items, net line as a non-cash adjustment on the Condensed Consolidated Statements of Cash Flows.
Condensed debtor in possession financial information	Condensed Combined Debtor-In-Possession Financial Information The financial statements below represent the condensed combined financial statements of the Company Parties (Debtors), which comprise the three legal entities which filed for bankruptcy in the U.S.. The company's entities which did not file bankruptcy are comprised primarily of the company's international entities and are not included in the Debtors' balance sheet, Debtors' statement of loss and Debtors' statement of cash flows below. Intercompany transactions among the Company Parties have been eliminated in the financial statements contained herein. Intercompany transactions among the Company Parties and the non-filing entities have not been eliminated in the Debtors' balance sheet. INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Statement of Comprehensive Income (Loss) (unaudited) Debtors' Statements of Loss (In thousands, except per share data) Three Months Ended March 31, 2023 Net sales $ 41,678 Cost of products sold 36,937 Gross Profit 4,741 Selling, general and administrative expenses 23,481 Gain on sale of business (4,212) Charges related to restructuring activities 3,749 Operating Loss (18,277) Net gain on convertible debt derivatives (85) Reorganization items, net 20,791 Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023) 9,241 Equity in earnings of non-debtor entities (7,057) Loss Before Income Taxes (41,167) Income tax provision 10 Net Loss $ (41,177) Other comprehensive income (loss): Defined benefit plans: Amortization of prior service costs and unrecognized losses 23 Deferred tax adjustment resulting from defined benefit plan activity (5) Valuation reserve associated with defined benefit plan activity 5 Other Comprehensive Income (Loss) 23 Comprehensive Loss $ (41,154) INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Balance Sheets (unaudited) Debtors' Balance Sheet March 31, Assets (In thousands) Current Assets Cash and cash equivalents $ 27,892 Trade receivables, net 18,595 Due from non-debtor affiliates 105,690 Inventories, net 28,171 Other current assets 10,664 Total Current Assets 191,012 Other Assets 2,593 Investment in subsidiaries 515,759 Intangibles, net 2,415 Property and Equipment, net 29,754 Finance Lease Assets, net 20,259 Operating Lease Assets, net 324 Total Assets $ 762,116 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 14,697 Due to non-debtor affiliates 117,233 Accrued expenses 30,481 Current taxes payable 758 Current portion of long-term debt 35,500 Current portion of finance lease obligations 1,642 Current portion of operating lease obligations 222 Total Current Liabilities 200,533 Long-Term Debt 137,228 Finance Lease Long-Term Obligations 21,166 Operating Leases Long-Term Obligations 83 Other Long-Term Obligations 5,063 Liabilities Subject to Compromise 287,626 Total Equity attributable to the debtors 110,417 Total Liabilities and Equity $ 762,116 INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Statements of Cash Flows (unaudited) Debtors' Statement of Cash Flows For the Three Months Ended March 31, 2023 Operating Activities (In thousands) Net loss $ (41,177) Adjustments to reconcile net loss to net cash used by operating activities: Gain on sale of business (4,212) Depreciation and amortization 1,895 Amortization of operating lease right of use assets 199 Provision for losses on trade and installment receivables 23 Provision for other deferred liabilities 169 Provision for equity compensation 181 Gain on disposals of property and equipment (88) Reorganization items, net (1) 5,464 Equity in earnings of non-debtor entities (7,057) Amortization of convertible debt discount, term loan original issuance discount and accretion of convertible debt 960 Amortization of debt fees 1,817 Net gain on convertible debt derivatives (85) Other non-cash 184 Changes in operating assets and liabilities: Trade receivables 5,159 Inventories, net 6,046 Other current assets (1,623) Accounts payable (2,254) Accrued expenses 13,931 Other long-term liabilities (945) Net Cash Used by Operating Activities (21,413) Investing Activities Purchases of property and equipment (54) Proceeds from sale of business 11,596 Change in other long-term assets (2) Other (540) Net Cash Provided by Investing Activities 11,000 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 43,042 Payments on revolving lines of credit, finance leases and intercompany loans (12,080) Payment of financing costs (1) (4,155) Net Cash Provided by Financing Activities 26,807 Effect of exchange rate changes on cash — Decrease in cash and cash equivalents 16,394 Cash and cash equivalents at beginning of year 11,498 Cash and cash equivalents at end of period $ 27,892 (1) Includes cash outflows of $3,664 for DIP financing costs.

Subsequent Events

Subsequent Events	2 Months Ended
	May 22, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Exiting Sanford, Florida Production and Distribution Facility On April 5, 2023, the company announced the decision to close its Sanford, Florida production and distribution facility, effective at the end of September 2023. The manufacturing and distribution activities currently conducted at the Sanford facility will be performed at other company locations or by third parties. The consolidation is expected to impact approximately 90 associates in Florida. This decision is supportive of the company’s transformation efforts and is part of the company’s long-term plan to increase enterprise value by targeting significant contributions from cost reduction activities in North America. The company expects to incur pre-tax cash restructuring charges of approximately $1.7 million in the North America segment, of which $0.9 million is expected to be incurred for severance and transition assistance and $0.8 million recognized for other closure-related costs. The charges are anticipated to be expensed in the second and third quarters of 2023, with the majority of cash payments expected to be made in third quarter of 2023, aligned with the planned timing for the exit of the facility. Termination of Information Technology Services Agreement Effective October 1, 2019, the company entered into a Master Information Technology Services Agreement (the “Master Services Agreement”) with Birlasoft Solutions Inc. and certain of its affiliates (collectively, “Birlasoft”), which are part of The CK Birla Group, to outsource substantially all of the company's information technology business service activities, including, among other things, support, rationalization and upgrading of the company's legacy information technology systems and implementation of a global enterprise resource planning system and eCommerce platform. On January 27, 2023, the company terminated the Master Services Agreement following Birlasoft's breach of the Master Services Agreement, including but not limited to Birlasoft's failure to meet transformation milestones, failure to provide services, and breach of representations, warranties and covenants in the Master Services Agreement. On April 24, 2023, the company reached a settlement with Birlasoft Solutions Inc. which was approved by the Bankruptcy Court, pursuant to which the company will make payments to Birlasoft in the aggregate amount of $2,000,000 for disengagement services to be completed by Birlasoft on or about May 31, 2023. Bankruptcy Emergence On April 28, 2023, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the First Amended Joint Chapter 11 Plan of Reorganization of Invacare Corporation and its Debtor Affiliates (Technical Modifications) (the “Plan”). On May 5, 2023, the Debtors satisfied the remaining conditions precedent to consummation of the Plan as set forth in the Plan, the Plan became effective in accordance with its terms, and the Debtors emerged from the Chapter 11 Cases without any need for further action or order of the Bankruptcy Court. In connection with the satisfaction of the conditions to effectiveness as set forth in the Confirmation Order and in the Plan, Invacare Corporation completed a series of transactions pursuant to which it became a wholly owned subsidiary of Invacare Holdings Corporation, a Delaware corporation, and conveyed certain of its foreign subsidiaries to a second wholly owned subsidiary of Invacare Holdings Corporation, Invacare Holdings Corp. On May 5, 2023, in connection with emergence from the Chapter 11 Cases, Invacare Holdings Corporation (A) entered into an Amended and Restated Credit Agreement, which amends, restates and replaces in its entirety the Credit Agreement, originally dated as of July 26, 2022, among Invacare Corporation, the lenders party thereto, Cantor Fitzgerald Securities, as administrative agent for the lenders thereunder, and GLAS Trust Corporation Limited, as collateral agent for the secured parties thereunder, with certain funds managed by Highbridge Capital Management, LLC, as the lenders, Cantor Fitzgerald Securities, as administrative agent, and GLAS Trust Company LLC, as collateral agent; (B) entered into a Loan and Security Agreement, among Invacare Holdings Corporation, Invacare Corporation, Medbloc, Inc., Invacare Canada L.P., Perpetual Motion Enterprises Limited, the guarantors party thereto, the several financial institution parties as lenders, and White Oak Commercial Finance, LLC, as administrative agent and collateral agent; (C) issued (i) $25,739,000 in aggregate principal amount of the Invacare Holdings Corporation’s new 7.50% Convertible Senior Secured Notes due 2028, Tranche I, issued pursuant to that certain indenture, by and among Invacare Holdings Corporation, the guarantors party thereto, and GLAS Company LLC, as trustee (in such capacity, the “Trustee”) and notes collateral agent (in such capacity, the “Collateral Agent”), and (ii) $20,736,000 in aggregate principal amount of Invacare Holdings Corporation’s new 7.50% Convertible Senior Secured Notes due 2028, Tranche II, issued pursuant to that certain indenture, by and among Invacare Holdings Corporation, the guarantors party thereto, the Trustee and the Collateral Agent; and (D) issued 9,999,980 shares of common stock (the “Common Stock”), par value $0.001 per share, and 6,750,011 shares of Invacare Holdings Corporation’s 9.00% Series A Convertible Participating Preferred Stock, par value $0.001 per share, (including the Common Stock that may be issued in exchange therefor); as further disclosed in the Current Report on 8-K filed by Invacare Holdings Corporation with the U.S. Securities and Exchange Commission on May 8, 2023. The company’s use of its net operating loss carryforwards is generally limited under section 382 of the Internal Revenue Code of 1986 (the “ IRC”) if the company undergoes an “ownership change.” When an “ownership change” occurs pursuant to a case commenced under chapter 11 of the Bankruptcy Code, the general limitation under section 382 of the IRC may not apply if certain requirements are satisfied under either section 382(l)(5) or section 382(l)(6) of the IRC. The company will experience an “ownership change” in connection with the reorganization, but the company has not yet determined whether it will be eligible for or rely on the special rule under section 382(l)(5) or the special rule under section 382(l)(6) of the IRC. If the company relies on section 382(l)(5) of the IRC, a second “ownership change” within two years from the Effective Date could eliminate completely the company’s ability to utilize its net operating loss carryovers. Regardless of whether the company relies on section 382(l)(5) of the IRC, an “ownership change” after the Effective Date could significantly limit the Company’s ability to utilize its net operating loss carryforwards for taxable years including or following such “ownership change.”

Accounting Policies (Policies)

Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation: The condensed consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of March 31, 2023 and the results of its operations and changes in its cash flow for the three months ended March 31, 2023 and 2022, respectively. The European segment's fiscal calendar runs December 1st through November 30th in order to meet filing deadlines. For the first quarter, the financial results are consolidated for the European segment using a February 28 quarter end for 2023 and 2022. This is consistent with prior filings the company has made historically. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates: The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

Receivables (Tables)

Receivables (Tables)	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Schedule of Accounts Receivable	Receivables consist of the following (in thousands): March 31, 2023 December 31, 2022 Accounts receivable, gross $ 101,991 $ 112,659 Customer rebate reserve (7,853) (11,569) Cash discount reserves (7,042) (8,756) Allowance for doubtful accounts (3,143) (3,279) Other, principally returns and allowances reserves (1,294) (1,103) Accounts receivable, net $ 82,659 $ 87,952
Schedule for Allowance for Credit Losses	The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Three Months Ended March 31, 2023 Balance as of beginning of period $ 3,279 Current period provision 24 Recoveries (direct write-offs), net (160) Balance as of end of period $ 3,143
Schedule of Installment Receivables	Installment receivables consist of the following (in thousands): March 31, 2023 December 31, 2022 Current Long-Term Total Current Long-Term Total Installment receivables $ 263 $ 197 $ 460 $ 311 $ 266 $ 577 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 263 $ 197 $ 460 $ 311 $ 266 $ 577
Schedule of Installment Receivables by Class	Installment receivables by class as of March 31, 2023 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 460 460 — — Total installment receivables $ 460 $ 460 $ — $ — Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total installment receivables $ 577 $ 577 $ — $ —
Schedule of Financing Receivables	Installment receivables by class as of March 31, 2023 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 460 460 — — Total installment receivables $ 460 $ 460 $ — $ — Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total installment receivables $ 577 $ 577 $ — $ —
Schedule of Aging of Installment Receivables	The aging of the company’s installment receivables was as follows (in thousands): March 31, 2023 December 31, 2022 Total Asia Pacific Total Asia Pacific Current $ 460 $ 460 $ 533 $ 533 0-30 days past due — — 44 44 31-60 days past due — — — — 61-90 days past due — — — — 90+ days past due — — — — $ 460 $ 460 $ 577 $ 577

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 50,385 $ 45,476 Finished goods 44,263 57,174 Work in process 8,987 9,911 Inventories, net $ 103,635 $ 112,561

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Other current assets consist of the following (in thousands): March 31, 2023 December 31, 2022 Tax receivables principally value added taxes $ 11,498 $ 22,946 Prepaid insurance 4,353 1,223 Prepaid inventory and freight 3,519 3,077 Service contracts 1,987 1,366 Receivable due from information technology provider 1,965 934 Recoverable income taxes 1,358 1,990 Derivatives (foreign currency forward exchange contracts) — 1,117 Deferred financing fees — 339 Prepaid and other current assets 8,267 6,710 Other Current Assets $ 32,947 $ 39,702

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets, Noncurrent	Other long-term assets consist of the following (in thousands): March 31, 2023 December 31, 2022 Cash surrender value of life insurance policies $ 2,708 $ 2,686 Deferred income taxes 1,330 1,102 Installment receivables 197 266 Investments 87 85 Deferred financing fees — 733 Other 288 287 Other Long-Term Assets $ 4,610 $ 5,159

Property And Equipment (Tables)

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment consist of the following (in thousands): March 31, 2023 December 31, 2022 Machinery and equipment $ 264,629 $ 269,835 Capitalized software 30,921 30,923 Land, buildings and improvements 25,554 25,095 Furniture and fixtures 8,113 8,053 Leasehold improvements 4,684 4,802 Property and Equipment, gross 333,901 338,708 Accumulated depreciation (283,387) (287,175) Property and Equipment, net $ 50,514 $ 51,533

Intangibles (Tables)

Intangibles (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): March 31, 2023 December 31, 2022 Historical Accumulated Historical Accumulated Customer lists $ 49,129 $ 49,129 $ 48,515 $ 48,515 Trademarks 19,116 — 18,867 — Developed technology 7,231 6,973 7,154 6,859 Patents 4,088 4,088 4,092 4,092 License agreements 3,982 1,591 3,981 1,480 Other 1,148 1,142 1,148 1,142 Intangibles $ 84,694 $ 62,923 $ 83,757 $ 62,088
Schedule of Finite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): March 31, 2023 December 31, 2022 Historical Accumulated Historical Accumulated Customer lists $ 49,129 $ 49,129 $ 48,515 $ 48,515 Trademarks 19,116 — 18,867 — Developed technology 7,231 6,973 7,154 6,859 Patents 4,088 4,088 4,092 4,092 License agreements 3,982 1,591 3,981 1,480 Other 1,148 1,142 1,148 1,142 Intangibles $ 84,694 $ 62,923 $ 83,757 $ 62,088

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of accruals for the following (in thousands): March 31, 2023 December 31, 2022 Salaries and wages $ 17,553 $ 19,307 Reorganization items, net 15,051 — Taxes other than income taxes, primarily value added taxes 12,084 27,106 IT service contracts 7,528 5,581 Warranty 7,026 7,981 Professional 6,616 11,267 Interest 6,359 6,900 Freight 4,324 4,542 Product line exit obligations 3,743 3,743 Product liability, current portion 2,344 2,125 Severance 1,979 3,472 Rebates 1,840 4,923 Deferred revenue 1,507 2,279 Insurance 770 951 Supplemental executive retirement program liability 391 391 Derivative liabilities (foreign currency forward exchange contracts) — 137 Other items, principally trade accruals 7,345 5,386 Accrued Expenses, prior to reclassification to Liabilities Subject to Compromise $ 96,460 $ 106,091 Less: Amounts reclassified to Liabilities Subject to Compromise 18,748 — Accrued Expenses $ 77,712 $ 106,091
Schedule of Product Warranty Liability	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2023 $ 7,981 Warranties provided during the period 396 Settlements made during the period (1,194) Changes in liability for pre-existing warranties during the period, including expirations (157) Balance as of March 31, 2023 $ 7,026

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt consists of the following (in thousands): March 31, 2023 December 31, 2022 Convertible senior notes Series I at 5.00%, due in November 2024 72,909 72,408 Convertible senior notes Series II at 5.00%, due in November 2024 77,758 76,719 Convertible senior notes at 4.25%, due in March 2026 69,700 67,665 Secured convertible senior notes at 5.68%, due in July 2026 37,404 37,240 Term loan, due in July 2026 50,954 82,808 DIP term loan, due upon emergence or by June 2, 2023 68,499 — Other obligations 16,040 17,401 Total debt, prior to reclassification to Liabilities Subject to Compromise 393,264 354,241 Less current maturities of long-term debt (35,656) (154) Less amounts reclassified to Liabilities Subject to Compromise 220,367 — Long-Term Debt $ 137,241 $ 354,087
Liability Components of Convertible 2024 Note	The liability components of the Series I 2024 Notes consist of the following (in thousands): March 31, 2023 December 31, 2022 Principal amount of liability component $ 72,909 $ 72,909 Debt fees — (501) Net carrying amount of liability component $ 72,909 $ 72,408
Liability Components of Convertible Series II 2024 Note	The liability components of the Series II 2024 Notes consist of the following (in thousands): March 31, 2023 December 31, 2022 Principal amount of liability component - including accretion $ 77,758 $ 77,309 Debt fees — (590) Net carrying amount of liability component $ 77,758 $ 76,719
Liability Components of Convertible 2026 Note	The liability components of the 2026 Notes consist of the following (in thousands): March 31, 2023 December 31, 2022 Principal amount of liability component $ 69,700 $ 69,700 Debt fees — (2,035) Net carrying amount of liability component $ 69,700 $ 67,665
Liability Components of Secured 2026 Notes	The liability components of the Secured 2026 Notes consist of the following (in thousands): March 31, 2023 December 31, 2022 Principal amount of liability component $ 41,475 $ 41,475 Unamortized discount (1,356) (1,447) Debt fees (2,715) (2,788) Net carrying amount of liability component $ 37,404 $ 37,240
Liability Components of Secured Term Loan	The liability components of the Secured Term Loan consist of the following (in thousands): March 31, 2023 December 31, 2022 Principal amount of liability component $ 55,500 $ 90,500 Unamortized original issuance discount (1,075) (1,846) Debt fees (3,471) (5,846) Net carrying amount of liability component $ 50,954 $ 82,808
DIP Term Loan	The liability components of the DIP Term Loan consist of the following (in thousands): March 31, 2023 Principal amount of liability component $ 70,000 Unamortized original issuance discount (352) Debt fees (1,149) Net carrying amount of liability component $ 68,499

Other Long-Term Obligations (Ta

Other Long-Term Obligations (Tables)	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Other Noncurrent Liabilities	Other long-term obligations consist of the following (in thousands): March 31, 2023 December 31, 2022 Deferred income taxes $ 19,139 $ 18,771 Product liability 11,023 10,438 Deferred compensation 4,914 4,970 Deferred gain on sale leaseback 4,747 4,834 Supplemental executive retirement plan liability 4,413 4,383 Uncertain tax obligation including interest 2,918 2,891 Death benefit obligation plan 2,616 2,533 Pension 1,055 1,019 Secured Convertible 2026 debt conversion liability — 85 Other 388 478 Other Long-Term Obligations, prior to reclassification to Liabilities Subject to Compromise $ 51,213 $ 50,402 Less: Amounts reclassified to Liabilities Subject to Compromise 21,563 — Other Long-Term Obligations $ 29,650 $ 50,402

Leases and Commitments (Tables)

Leases and Commitments (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Lease, Cost [Table]	Lease expenses for the three months ended March 31, 2023 and March 31, 2022, respectively, were as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Operating leases $ 1,548 $ 1,610 Variable and short-term leases 610 714 Total operating leases $ 2,158 $ 2,324 Finance lease interest cost $ 1,067 $ 1,083 Finance lease depreciation 1,067 1,092 Total finance leases $ 2,134 $ 2,175
Schedule of Cash Flow, Supplemental Disclosures [Table]	Supplemental cash flow amounts for the three months ended March 31, 2023 and March 31, 2022 were as follows (in thousands): For the Three Months Ended March 31, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2023 2022 Operating leases $ 1,528 $ 2,239 Finance leases 1,843 1,829 Total $ 3,371 $ 4,068 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2023 2022 Operating leases $ 2,631 $ 716 Finance leases 5 175 Total $ 2,636 $ 891
Weighted-Average Remaining Lease Terms and Discount Rates [Table]	Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of March 31, 2023 and December 31, 2022, respectively: March 31, 2023 December 31, 2022 Weighted-average remaining lease term - finance leases 14.5 years 14.8 years Weighted-average remaining lease term - operating leases 4.1 years 4.6 years Weighted-average discount rate - finance leases 3.74% 3.74% Weighted-average discount rate - operating leases 15.36% 9.36%
Lessee, Operating Lease, Liability, Maturity	Future minimum operating and finance lease commitments, as of March 31, 2023, are as follows (in thousands): Finance Operating Leases 2023 $ 5,151 $ 3,689 2024 6,808 3,894 2025 6,710 2,539 2026 6,599 1,224 2027 6,485 392 Thereafter 63,035 1,356 Total future minimum lease payments 94,788 13,094 Amounts representing interest (33,818) (996) Present value of minimum lease payments 60,970 12,098 Less: current maturities of lease obligations (3,162) (4,142) Long-term lease obligations $ 57,808 $ 7,956
Finance Lease, Liability, Fiscal Year Maturity	Future minimum operating and finance lease commitments, as of March 31, 2023, are as follows (in thousands): Finance Operating Leases 2023 $ 5,151 $ 3,689 2024 6,808 3,894 2025 6,710 2,539 2026 6,599 1,224 2027 6,485 392 Thereafter 63,035 1,356 Total future minimum lease payments 94,788 13,094 Amounts representing interest (33,818) (996) Present value of minimum lease payments 60,970 12,098 Less: current maturities of lease obligations (3,162) (4,142) Long-term lease obligations $ 57,808 $ 7,956

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements	The following tables disaggregate the company’s revenues by major source and by reportable segment for the three months ended March 31, 2023 and March 31, 2022 (in thousands): Three Months Ended March 31, 2023 Product Service Total Europe $ 101,874 $ 3,049 $ 104,923 North America 51,906 458 52,364 All Other 6,876 1,318 8,194 Total $ 160,656 $ 4,825 $ 165,481 % Split 97% 3% 100% Three Months Ended March 31, 2022 Product Service Total Europe $ 115,265 $ 2,814 $ 118,079 North America 75,183 136 75,319 All Other 6,382 1,208 7,590 Total $ 196,830 $ 4,158 $ 200,988 % Split 98% 2% 100%

Equity Compensation (Tables)

Equity Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Restricted stock and restricted stock units $ 235 $ 655 Performance shares and performance share units (54) (345) Total stock-based compensation expense $ 181 $ 310
Schedule of Unrecognized Compensation Cost, Nonvested Awards	As of March 31, 2023, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan, which is related to non-vested awards, was as follows (in thousands): March 31, 2023 Restricted stock and restricted stock units $ 1,836 Performance shares and performance share units 2 Total unrecognized stock-based compensation expense $ 1,838
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about stock option activity for the three months ended March 31, 2023: 2023 Weighted Average Options outstanding at January 1, 2023 189,689 $ 13.43 Forfeited (103,462) 14.49 Options outstanding at March 31, 2023 86,227 $ 12.15 Options exercise price range at March 31, 2023 $ 12.15 to $ 12.15 Options exercisable at March 31, 2023 86,227 Shares available for grant under the 2018 Plan at March 31, 2023* 5,329,514 ________ * Shares available for grant under the 2018 Plan as of March 31, 2023 are reduced by awards and increased by forfeitures or expirations. At March 31, 2023, an aggregate of 1,466,569 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.
Schedule of Share-based Compensation, Stock Options Outstanding	The following table summarizes information about stock options outstanding at March 31, 2023: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Exercisable at Weighted Average $12.15 – $20.00 86,227 3.96 $ 12.15 86,227 $ 12.15
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): 2023 Weighted Average Fair Value Stock / Units unvested at January 1, 2023 1,061,867 $ 2.75 Forfeited (23,601) 3.35 Stock / Units unvested at 1,038,266 $ 2.73
Share-based Compensation, Performance Shares Award Unvested Activity	The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): 2023 Weighted Average Fair Value Shares / Units unvested at January 1, 2023 318,071 $ 5.15 Shares / Units unvested at 318,071 $ 5.15

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) by Component (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2022 $ (23,879) $ (3,230) $ 2,386 $ — $ (24,723) OCI before reclassifications 6,283 (470) (77) (93) 5,643 Amount reclassified from accumulated OCI — — 107 93 200 Net current-period OCI 6,283 (470) 30 — 5,843 March 31, 2023 $ (17,596) $ (3,700) $ 2,416 $ — $ (18,880) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (6,768) 426 318 875 (5,149) Amount reclassified from accumulated OCI — — (94) (51) (145) Net current-period OCI (6,768) 426 224 824 (5,294) March 31, 2022 $ 12,193 $ 2,553 $ (3,877) $ 825 $ 11,694
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended March 31, 2023 2022 Defined Benefit Plans Service and interest costs $ 107 $ (94) Selling, general and administrative expenses Tax — — Income taxes Total after tax $ 107 $ (94) Derivatives Foreign currency forward contracts hedging sales $ — $ (27) Net sales Foreign currency forward contracts hedging purchases 133 (31) Cost of products sold Total loss (income) before tax 133 (58) Tax (40) 7 Income taxes Total after tax $ 93 $ (51)

Charges Related To Restructur_2

Charges Related To Restructuring Activities (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	A progression by reporting segment of the accruals recorded as a result of the restructuring for the three months ended March 31, 2023 is as follows (in thousands): Severance Contract Terminations Other Total December 31, 2022 Balances North America $ 967 $ — $ 3,026 $ 3,993 Europe 1,314 — 1,493 2,807 All Other 1,191 — — 1,191 Total 3,472 — 4,519 7,991 Charges North America 57 — 3,665 3,722 Europe 78 654 240 972 All Other — — — — Total 135 654 3,905 4,694 Payments North America (591) — (6,691) (7,282) Europe (849) (654) (1,733) (3,236) All Other (188) — — (188) Total (1,628) (654) (8,424) (10,706) March 31, 2023 Balances North America 433 — — 433 Europe 543 — — 543 All Other 1,003 — — 1,003 Total $ 1,979 $ — $ — $ 1,979

Net Earnings (Loss) Per Commo_2

Net Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended March 31, 2023 2022 Basic Weighted average common shares outstanding 37,994 35,046 Net loss $ (41,177) $ (24,197) Net loss per common share $ (1.08) $ (0.69) Diluted Weighted average common shares outstanding 37,994 35,046 Share options and awards 43 373 Weighted average common shares assuming dilution 38,037 35,419 Net loss $ (41,177) $ (24,197) Net loss per common share * $ (1.08) $ (0.69) ________ * Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2023 and 2022, respectively, and outstanding were as follows (in thousands USD): March 31, 2023 December 31, 2022 Notional Gain Notional Gain USD / EUR — — 60,964 980 $ — $ — $ 60,964 $ 980
Schedule of Derivatives Instruments Statements of Financial Position, Fair Value	The fair values of the company’s derivative instruments were as follows (in thousands): March 31, 2023 December 31, 2022 Assets Liabilities Assets Liabilities Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts — — 1,117 137 Total derivatives $ — $ — $ 1,117 $ 137
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of derivative instruments on Accumulated Other Comprehensive Income (Loss) (OCI) and the condensed consolidated Statements of comprehensive income (loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended March 31, 2023 Foreign currency forward exchange contracts $ (93) $ (93) $ — Three months ended March 31, 2022 Foreign currency forward exchange contracts $ 875 $ 51 $ — Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended March 31, 2022 Foreign currency forward exchange contracts $ 602
Fair Value of Convertible Note Derivative	The fair values of the outstanding convertible note derivatives as of March 31, 2023 and their effect on the Statement of Comprehensive Income (Loss) were as follows (in thousands): Fair Value Gain Secured Convertible 2026 Notes conversion long-term liability $ — $ 85

Fair Values (Tables)

Fair Values (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III December 31, 2022 Forward exchange contracts—net — $ 980 — Secured convertible 2026 debt conversion liability — $ (85) —
Fair Value, by Balance Sheet Grouping	The carrying values and fair values of the company’s financial instruments are as follows (in thousands): March 31, 2023 December 31, 2022 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 66,284 $ 66,284 $ 58,792 $ 58,792 Forward contracts in Other current assets — — 1,117 1,117 Forward contracts in Accrued expenses — — (137) (137) Total debt (including current maturities of long-term debt) * (393,264) (170,940) (354,241) (278,027) Series I 2024 Notes (72,909) (3,645) (72,408) (62,460) Series II 2024 Notes (77,758) (3,888) (76,719) (64,678) 2026 Notes (69,700) (3,485) (67,665) (32,276) 2026 Secured Notes (37,404) (27,529) (37,240) (34,341) 2026 Term Loan (50,954) (47,854) (82,808) (66,871) DIP Term Loan (68,499) (68,499) — — Other (16,040) (16,040) (17,401) (17,401) Secured convertible 2026 debt conversion liability in Other Long-Term Obligations — — (85) (85) ________ * The company's total debt is shown net of discount and fees on the company's condensed consolidated balance sheets. Accordingly, the fair values included in the long-term debt presented in this table are also shown net of discount and fees. Total debt amounts exclude operating and finance lease obligations.

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The information by segment is as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Revenues from external customers Europe $ 104,923 $ 118,079 North America 52,364 75,319 All Other (Asia Pacific) 8,194 7,590 Consolidated $ 165,481 $ 200,988 Intersegment revenues Europe $ 4,431 $ 4,435 North America 6,842 11,096 All Other (Asia Pacific) 10 — Consolidated $ 11,283 $ 15,531 Restructuring charges before income taxes Europe $ 972 $ 2,119 North America 3,722 1,662 All Other — 9 Consolidated $ 4,694 $ 3,790 Operating income (loss) Europe $ 6,170 $ 3,225 North America (10,315) (8,336) All Other (5,820) (7,724) Charges related to restructuring activities (4,694) (3,790) Net gain on sale of businesses 4,212 — Consolidated operating loss (10,447) (16,625) Net gain on convertible debt derivatives 85 — Net interest expense (9,084) (6,252) Reorganization items, net (20,791) — Loss before income taxes $ (40,237) $ (22,877)
Revenue from External Customer [Line Items]
Revenue from External Customers by Products and Services [Table Text Block]	Net sales by product, are as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Europe Lifestyle $ 52,802 $ 61,064 Mobility and Seating 42,916 47,402 Respiratory Therapy 4,692 4,663 Other(1) 4,513 4,950 $ 104,923 $ 118,079 North America Lifestyle $ 28,049 $ 34,301 Mobility and Seating 22,312 25,422 Respiratory Therapy 1,545 15,460 Other(1) 458 136 $ 52,364 $ 75,319 All Other (Asia Pacific) Mobility and Seating $ 2,384 $ 2,690 Lifestyle 2,758 2,826 Respiratory Therapy 1,639 779 Other(1) 1,413 1,295 $ 8,194 $ 7,590 Total Consolidated $ 165,481 $ 200,988 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Reorganizations (Tables)

Reorganizations (Tables)	3 Months Ended
	Mar. 31, 2023
Reorganizations [Abstract]
Liabilities subject to compromise	Liabilities Subject to Compromise at March 31, 2023 consisted of the following (in thousands): March 31, 2023 Current liabilities Accounts payable $ 26,948 Accrued expenses 18,748 Total current liabilities 45,696 Long-term debt 220,367 Other long-term obligations 21,563 Total Liabilities Subject to Compromise $ 287,626
Reorganization, Chapter 11	Reorganization items incurred as a result of the Chapter 11 Cases are presented separately in the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2023 and consist of the following (in thousands): For the Three Months Ended March 31, 2023 Professional fees $ 13,598 DIP financing costs 5,474 Write-off of pre-petition debt issuance costs 4,060 Gain on settlements of pre-petition claims (2,341) Reorganization items, net $ 20,791
Condensed combined debtor-in-possession comprehensive income statement	INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Statement of Comprehensive Income (Loss) (unaudited) Debtors' Statements of Loss (In thousands, except per share data) Three Months Ended March 31, 2023 Net sales $ 41,678 Cost of products sold 36,937 Gross Profit 4,741 Selling, general and administrative expenses 23,481 Gain on sale of business (4,212) Charges related to restructuring activities 3,749 Operating Loss (18,277) Net gain on convertible debt derivatives (85) Reorganization items, net 20,791 Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023) 9,241 Equity in earnings of non-debtor entities (7,057) Loss Before Income Taxes (41,167) Income tax provision 10 Net Loss $ (41,177) Other comprehensive income (loss): Defined benefit plans: Amortization of prior service costs and unrecognized losses 23 Deferred tax adjustment resulting from defined benefit plan activity (5) Valuation reserve associated with defined benefit plan activity 5 Other Comprehensive Income (Loss) 23 Comprehensive Loss $ (41,154)
Condensed combined debtor-in-possession cash flow statement	INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Statements of Cash Flows (unaudited) Debtors' Statement of Cash Flows For the Three Months Ended March 31, 2023 Operating Activities (In thousands) Net loss $ (41,177) Adjustments to reconcile net loss to net cash used by operating activities: Gain on sale of business (4,212) Depreciation and amortization 1,895 Amortization of operating lease right of use assets 199 Provision for losses on trade and installment receivables 23 Provision for other deferred liabilities 169 Provision for equity compensation 181 Gain on disposals of property and equipment (88) Reorganization items, net (1) 5,464 Equity in earnings of non-debtor entities (7,057) Amortization of convertible debt discount, term loan original issuance discount and accretion of convertible debt 960 Amortization of debt fees 1,817 Net gain on convertible debt derivatives (85) Other non-cash 184 Changes in operating assets and liabilities: Trade receivables 5,159 Inventories, net 6,046 Other current assets (1,623) Accounts payable (2,254) Accrued expenses 13,931 Other long-term liabilities (945) Net Cash Used by Operating Activities (21,413) Investing Activities Purchases of property and equipment (54) Proceeds from sale of business 11,596 Change in other long-term assets (2) Other (540) Net Cash Provided by Investing Activities 11,000 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 43,042 Payments on revolving lines of credit, finance leases and intercompany loans (12,080) Payment of financing costs (1) (4,155) Net Cash Provided by Financing Activities 26,807 Effect of exchange rate changes on cash — Decrease in cash and cash equivalents 16,394 Cash and cash equivalents at beginning of year 11,498 Cash and cash equivalents at end of period $ 27,892 (1) Includes cash outflows of $3,664 for DIP financing costs.
Condensed combined debtor-in-possession combined balance sheet	INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Balance Sheets (unaudited) Debtors' Balance Sheet March 31, Assets (In thousands) Current Assets Cash and cash equivalents $ 27,892 Trade receivables, net 18,595 Due from non-debtor affiliates 105,690 Inventories, net 28,171 Other current assets 10,664 Total Current Assets 191,012 Other Assets 2,593 Investment in subsidiaries 515,759 Intangibles, net 2,415 Property and Equipment, net 29,754 Finance Lease Assets, net 20,259 Operating Lease Assets, net 324 Total Assets $ 762,116 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 14,697 Due to non-debtor affiliates 117,233 Accrued expenses 30,481 Current taxes payable 758 Current portion of long-term debt 35,500 Current portion of finance lease obligations 1,642 Current portion of operating lease obligations 222 Total Current Liabilities 200,533 Long-Term Debt 137,228 Finance Lease Long-Term Obligations 21,166 Operating Leases Long-Term Obligations 83 Other Long-Term Obligations 5,063 Liabilities Subject to Compromise 287,626 Total Equity attributable to the debtors 110,417 Total Liabilities and Equity $ 762,116

Accounting Policies (Details)

Accounting Policies (Details) - Subsequent Event	May 05, 2023 USD ($)
Subsequent Event [Line Items]
Convertible Notes Payable	$ 46,475,000
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value	75,000,000
New ABL advance	$ 13,400,000

Accounting Policies (Details)_2

Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Long term debt reclassed to liabilities subject to compromise	$ 220,367	$ 0

Divested Businesses (Details)

Divested Businesses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Divested Businesses [Abstract]
Proceeds from sale of businesses	$ 11,596,000	$ 0
Net gain on sale of businesses	4,212,000	0
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net gain on sale of businesses	4,212,000	$ 0
Proceeds from Divestiture of Businesses	$ 11,925,644

Receivables (Narrative) (Detail

Receivables (Narrative) (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) payment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Contingent Liability, Guarantee	$ 286,000
Number of missed payments before delinquent | payment	3
Credit amount requiring additional analysis	$ 250,000
Average period of adjudication	18 months
Risk Level, Low
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, North America excluding Canada	1%
Receivables, Expected Loss Percentage, Canada	0.10%
Receivables, Expected Loss Percentage, Europe	0.30%
Receivables, Expected Loss Percentage, AsiaPac	1%
Risk Level, Medium
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	0.80%
Risk Level, High
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	2.30%

Receivables (Schedule of Accoun

Receivables (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Accounts Receivable [Abstract]
Accounts receivable, gross	$ 101,991	$ 112,659
Customer rebate reserve	(7,853)	(11,569)
Cash discount reserves	(7,042)	(8,756)
Allowance for doubtful accounts	(3,143)	(3,279)
Other, principally returns and allowances reserves	(1,294)	(1,103)
Accounts Receivable, Net	$ 82,659	$ 87,952

Receivables Schedule for Allowa

Receivables Schedule for Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Financing Receivable, Allowance for Credit Losses [Line Items]
Allowance for Credit Losses	$ 3,143	$ 3,279
Allowance for Loan and Lease Losses, Adjustments, Other	24
Financing Receivable, Allowance for Credit Losses, Write-downs	$ 160

Receivables (Installment Receva

Receivables (Installment Recevables) (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Installment Receivables, Current	$ 263,000	$ 311,000
Installment Receivables, Long-Term	197,000	266,000
Total Installment Receivables	460,000	577,000
Total Unearned Interest	(1,507,000)	(2,279,000)
Allowance for doubtful accounts, current	0	0
Allowance for doubtful accounts, long-term	0	0
Allowance for doubtful accounts	0	0
Installment receivables, net	263,000	311,000
Installment receivables, net, long-term	197,000	266,000
Installment receivables, net	$ 460,000	$ 577,000

Receivables (Rollforward of All

Receivables (Rollforward of Allowance for Doubtful Accounts) (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Allowance for Doubtful Accounts [Roll Forward]
Financing Receivable, Allowance for Credit Loss, Beginning Balance	$ 0
Financing Receivable, Allowance for Credit Loss, Ending Balance	$ 0

Receivables (Installment Receiv

Receivables (Installment Receivables by Class) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Dec. 31, 2022
Total Installment Receivables
Total installment receivables	$ 460		$ 577
Unpaid Principal Balance
Total installment receivables	460		577
Related Allowance for Doubtful Accounts
Impaired Financing Receivable, Related Allowance	0		0
Interest Income Recognized
Total installment receivables	0	$ 0
All Other
Total Installment Receivables
Non-impaired installment receivables with no related allowance recorded	460		577
Unpaid Principal Balance
Non-impaired installment receivables with no related allowance recorded	460		577
Non-Impaired Financing Receivable, Related Allowance	0		$ 0
Interest Income Recognized
Non-impaired installment receivables with no related allowance recorded	$ 0	$ 0

Receivables (Aging of Installme

Receivables (Aging of Installment Receivables) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	$ 0	$ 44
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	0	0
Installment Receivable, Not Past Due	460	533
Financing Receivable, Gross	460	577
All Other
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	0	44
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	0	0
Installment Receivable, Not Past Due	460	533
Financing Receivable, Gross	$ 460	$ 577

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 44,263	$ 57,174
Raw materials	50,385	45,476
Work in process	8,987	9,911
Inventories, net	$ 103,635	$ 112,561

Other Current Assets Components

Other Current Assets Components of Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Tax receivables principally value added taxes	$ 11,498	$ 22,946
Prepaid inventory and freight	3,519	3,077
Receivable due from information technology provider	1,965	934
Prepaid insurance	4,353	1,223
Derivatives (foreign currency forward exchange contracts)	0	1,117
Recoverable income taxes	1,358	1,990
Service contracts	1,987	1,366
Deferred financing fees	0	339
Prepaid and other current assets	8,267	6,710
Other current assets	$ 32,947	$ 39,702

Other Long-Term Assets Componen

Other Long-Term Assets Components of Other Long-Term Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of life insurance policies	$ 2,708	$ 2,686
Deferred income taxes	1,330	1,102
Installment receivables	197	266
Deferred financing fees	0	733
Investments	87	85
Other	288	287
Other Long-Term Assets	$ 4,610	$ 5,159

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 333,901,000		$ 338,708,000
Less allowance for depreciation	(283,387,000)		(287,175,000)
Property and equipment, net	50,514,000		51,533,000
Capitalized Computer Software, Net	25,180,000		26,015,000
Computer Software Depreciation Expense	833,000	$ 677,000
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	264,629,000		269,835,000
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,554,000		25,095,000
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,113,000		8,053,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,684,000		4,802,000
Capitalized Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 30,921,000		$ 30,923,000

Intangibles (Narrative) (Detail

Intangibles (Narrative) (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 153,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	7 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	5 years 4 months 24 days

Intangibles (Intangible Table)

Intangibles (Intangible Table) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 84,694	$ 83,757
Accumulated Amortization	62,923	62,088
Customer lists
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	49,129	48,515
Accumulated Amortization	49,129	48,515
Developed technology
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	7,231	7,154
Accumulated Amortization	6,973	6,859
Patents
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	4,088	4,092
Accumulated Amortization	4,088	4,092
License agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	3,982	3,981
Accumulated Amortization	1,591	1,480
Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,148	1,148
Accumulated Amortization	1,142	1,142
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 19,116	$ 18,867

Intangibles (Finite-Lived Intan

Intangibles (Finite-Lived Intangible Asset Future Amortization Expense) (Details)	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future amortization expense, remainder of fiscal year	$ 611,000
Future amortization expense, 2022	568,000
Future amortization expense, 2023	439,000
Future amortization expense, 2024	437,000
Future amortization expense, 2025	310,000
Future amortization expense, 2026	$ 212,000

Accrued Expenses Components of

Accrued Expenses Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Taxes other than income taxes, primarily value added taxes	$ 12,084	$ 27,106
Salaries and wages	17,553	19,307
Accrued expenses for reorganization items	15,051	0
Warranty	7,026	7,981
Professional	6,616	11,267
Freight	4,324	4,542
Interest	6,359	6,900
IT service contracts	7,528	5,581
Deferred revenue	1,507	2,279
Severance	1,979	3,472
Restructuring Reserve, Current	3,743	3,743
Rebates	1,840	4,923
Product liability, current portion	2,344	2,125
Derivative liabilities (foreign currency forward exchange contracts)	0	137
Insurance	770	951
Supplemental executive retirement program liability	391	391
Other items, principally trade accruals	7,345	5,386
Accrued expenses	77,712	106,091
Liabilities subject to compromise, accrued expenses	18,748	0
Accrued expenses prior to reclass to liabilities subject to compromise	$ 96,460	$ 106,091

Accrued Expenses Warranty Sched

Accrued Expenses Warranty Schedule (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Product Liability Contingency
Balance as of January 1, 2023	$ 7,981
Warranties provided during the period	396
Settlements made during the period	(1,194)
Changes in liability for pre-existing warranties during the period, including expirations	(157)
Balance as of March 31, 2023	$ 7,026

Long-Term Debt (Details)

Long-Term Debt (Details)	3 Months Ended					12 Months Ended
	Mar. 31, 2023 USD ($) d $ / shares shares	Sep. 30, 2022 shares	Mar. 31, 2022 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2022 USD ($)	Feb. 02, 2023 USD ($)	Jan. 31, 2023 USD ($)	Dec. 23, 2022 USD ($)	Oct. 03, 2022 USD ($)	Jul. 26, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Mar. 11, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2017 USD ($)
Debt Instrument [Line Items]
Total debt, prior to reclassification to liabilities subject to compromise	$ 393,264,000					$ 354,241,000
Long-term Debt and Capital Lease Obligations, Current	(35,656,000)					(154,000)
Long term debt reclassed to liabilities subject to compromise	220,367,000					0
Long-term debt net of current maturities	137,241,000					354,087,000
Accretion Expense	$ 449,000		$ 911,000
Accretion Rate	4.70%
Lifetime to date - Accretion Expense	$ 8,883,000
Debtor-in-Possession Financing, Borrowings Outstanding	68,499,000					0
Debtor-in-Possession Financing, Amount Arranged								$ 70,000,000
Debtor-in-Possession Financing, Interest Rate on Borrowings Outstanding								15%
DIP ABL interest rate								4.25%
Debtor in Possession, Line of Credit Facility								$ 17,425,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument Exchange Amount				$ 35,375,000	$ 72,909,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	72,909,000					72,909,000
Debt Instrument, Fee Amount	0					(501,000)
Debt Instrument, Net Carrying Amount	$ 72,909,000					72,408,000
Interest rate (as a percent)	5%
Debt Instrument Repurchase Amount, Cash Paid														$ 6,928,000
Debt Instrument, Increase, Accrued Interest	$ 303,000		911,000
Percent of the Applicable Conversion Price	130%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Business Day Period	5 years
Percent of the Product of the Last Reported Sale Price, Common Shares	98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.80%
Unamortized Debt Issuance Expense	$ 479,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	77,758,000					77,309,000
Debt Instrument, Fee Amount	0					(590,000)
Debt Instrument, Net Carrying Amount	$ 77,758,000					76,719,000
Interest rate (as a percent)	5%
Debt Instrument Repurchase Amount, Cash Paid												$ 5,593,000
Debt Instrument Exchange Amount				73,875,000
Debt Instrument, Increase, Accrued Interest	$ 287,000		923,000
Percent of the Applicable Conversion Price	130%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	9%
Unamortized Debt Issuance Expense	$ 564,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	69,700,000					69,700,000
Debt Instrument, Fee Amount	0					(2,035,000)
Debt Instrument, Net Carrying Amount	$ 69,700,000					67,665,000
Interest rate (as a percent)	4.25%
Debt Instrument Exchange Amount						55,300,000
Debt Instrument, Increase, Accrued Interest	$ 247,000		$ 1,328,000
Percent of the Applicable Conversion Price	130%
Last Reported Sales Price Period, Common Stock	20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days	30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000
Business Day Period	5 days
Debt Instrument, Convertible, Threshold Trading Days	10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	94.6096
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 10.57
Unamortized Debt Issuance Expense	$ 1,982,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount															$ 120,000,000
Interest rate (as a percent)	4.50%
Debt Instrument Repurchase Amount, Cash Paid	$ 2,650,000
Debt Instrument Exchange Amount				$ 38,500,000
Class of Warrant or Right, Outstanding | shares	1,113,854
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 72,909,000					72,408,000
Debt Instrument, Convertible, Threshold Trading Days	10
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 77,758,000					76,719,000
Business Day Period	5 years
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 125,000,000
Long-term debt	$ 69,700,000					67,665,000
Interest rate (as a percent)	4.25%
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 - July 26, 2022 Issuance [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 37,404,000					37,240,000
Debt Instrument, Increase, Accrued Interest	$ 589,000
Debt Instrument, Fee Amount											$ 3,099,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.60%
Convertible Subordinated Debt | Secured Term Loans due July 2026 (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 18,500,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain]
Debt Instrument [Line Items]
Interest rate (as a percent)											5.68%
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount						41,475,000
Debt Instrument, Unamortized Discount	$ (1,356,000)					(1,447,000)
Debt Instrument, Fee Amount	$ (2,715,000)					(2,788,000)
Debt Instrument, Convertible, Threshold Consecutive Trading Days | d	30
Debt Instrument, Non-Cash Interest Expense Recognized in the Period	$ 91,000
Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)
Debt Instrument [Line Items]
Unamortized Debt Issuance Expense	1,036,000
Other Notes and Capital Lease Obligations
Debt Instrument [Line Items]
Long-term debt	16,040,000					17,401,000
Secured Term Loan - issuance July 26th, 2022 [Domain] | Secured Term Loans due July 2026 [Domain]
Debt Instrument [Line Items]
Long-term debt						82,808,000
Secured Debt | Secured Term Loans due July 2026 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	55,500,000					90,500,000					$ 104,500,000
Long-term debt	50,954,000					82,808,000
Debt Instrument, Unamortized Discount	(1,075,000)					(1,846,000)
Debt Instrument, Fee Amount	(3,471,000)					(5,846,000)
Debt Instrument, Increase, Accrued Interest	$ 2,225,000
Debt Instrument, Fee Amount											6,480,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	14.90%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period	$ 420,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Additional amount after closing (round 2) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											8,500,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Additional amount after closing (round 4) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount									$ 14,000,000		19,500,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Initial amount at closing [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 66,500,000
Secured Debt | Secured Term Loans due July 2026 (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount									$ 5,500,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain]
Debt Instrument [Line Items]
Interest rate (as a percent)											5.68%
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Convertible Preferred Stock, Shares Issued upon Conversion | shares											333.3333
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 3
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Interest rate (as a percent)											5.68%
Percent of the Applicable Conversion Price											150%
Last Reported Sales Price Period, Common Stock	20 days
Convertible Senior Notes, Percentage of Principal Required for Repurchase											100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Debt Instrument, Common Shares Exchanged | shares		2,700,000
Secured Debt | Debtor in Possession (DIP) Term Loan
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 70,000,000						$ 35,500,000
Debt Instrument, Unamortized Discount	(352,000)
Debt Instrument, Fee Amount	(1,149,000)
Debt Instrument, Increase, Accrued Interest	$ 2,639,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	19.30%
Debt Instrument, Non-Cash Interest Expense Recognized in the Period	$ 1,501,000
Secured Debt | Debtor in Possession (DIP) Term Loan | Additional amount after closing (round 2) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							35,000,000
Secured Debt | Debtor in Possession (DIP) Term Loan | Initial amount at closing [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 35,000,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding						$ 15,220,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (DIP ABL Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	13,870,000
Line Of Credit Facility Gross Borrowing Base	$ 14,023,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement) | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%

Long-Term Debt Components of Co

Long-Term Debt Components of Convertible Debt (Details) - Convertible Subordinated Debt - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	$ 303,000	$ 911,000
Debt Instrument, Face Amount	$ 72,909,000		$ 72,909,000
Interest rate (as a percent)	5%
Debt fees	$ 0		(501,000)
Debt Instrument, Net Carrying Amount	72,909,000		72,408,000
Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	247,000	$ 1,328,000
Debt Instrument, Face Amount	$ 69,700,000		69,700,000
Interest rate (as a percent)	4.25%
Debt fees	$ 0		(2,035,000)
Debt Instrument, Net Carrying Amount	69,700,000		67,665,000
Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount			41,475,000
Unamortized discount	(1,356,000)		(1,447,000)
Debt fees	(2,715,000)		(2,788,000)
Convertible Senior Secured Notes at 5.68% July 2026 - July 26, 2022 Issuance [Domain]
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	589,000
Long-term debt	$ 37,404,000		$ 37,240,000

Long-Term Debt Narrative (Detai

Long-Term Debt Narrative (Details)

3 Months Ended

12 Months Ended

Jun. 30, 2023

Mar. 31, 2023 USD ($) d $ / shares shares

Sep. 30, 2022 shares

Mar. 31, 2022 USD ($)

Jun. 30, 2020 USD ($)

Dec. 31, 2019 USD ($)

Jun. 30, 2017 USD ($) $ / shares

Dec. 31, 2022 USD ($)

May 05, 2023 USD ($)

Dec. 23, 2022 USD ($)

Jul. 26, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($)

Mar. 11, 2021 USD ($)

Dec. 31, 2020 USD ($)

Debt Instrument [Line Items]

Amortization of debt fees

$ 1,817,000

$ 615,000

Cash surrender value of life insurance policies

2,708,000

$ 2,686,000

Borrowing against Cash Surrender Value of Life Insurance

2,000,000

Accretion Expense

$ 449,000

911,000

Accretion Rate

4.70%

Lifetime to date - Accretion Expense

$ 8,883,000

Subsequent Event

Debt Instrument [Line Items]

Borrowing capacity

$ 40,000,000

Debt Instrument, Face Amount

$ 85,000,000

Secured Term Loans due July 2026 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

$ 2,000,000

Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 72,909,000

72,909,000

Interest rate (as a percent)

5%

Debt Instrument Repurchase Amount, Cash Paid

$ 6,928,000

Last Reported Sales Price Period, Common Stock

20 days

Debt Instrument, Convertible, Threshold Consecutive Trading Days

30

Percent of the Applicable Conversion Price

130%

Business Day Period

5 years

Percent of the Product of the Last Reported Sale Price, Common Shares

98%

Convertible Senior Notes, Percentage of Principal Required for Repurchase

100%

Convertible Preferred Stock, Shares Issued upon Conversion | shares

67.6819

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 14.78

Debt Instrument, Net Carrying Amount

$ 72,909,000

72,408,000

Debt Instrument, Fee Amount

0

(501,000)

Debt Instrument, Increase, Accrued Interest

$ 303,000

911,000

Debt Instrument, Interest Rate on Liability Component, Effective Percentage

8.80%

Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021

Debt Instrument [Line Items]

Debt Instrument Exchange Amount

$ 35,375,000

$ 72,909,000

Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 77,758,000

77,309,000

Interest rate (as a percent)

5%

Debt Instrument Exchange Amount

73,875,000

Debt Instrument Repurchase Amount, Cash Paid

$ 5,593,000

Last Reported Sales Price Period, Common Stock

20 days

Debt Instrument, Convertible, Threshold Consecutive Trading Days

30

Percent of the Applicable Conversion Price

130%

Debt Instrument, Convertible, Threshold Trading Days

10

Percent of the Product of the Last Reported Sale Price, Common Shares

98%

Convertible Senior Notes, Percentage of Principal Required for Repurchase

100%

Convertible Preferred Stock, Shares Issued upon Conversion | shares

67.6819

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 14.78

Debt Instrument, Net Carrying Amount

$ 77,758,000

76,719,000

Debt Instrument, Fee Amount

0

(590,000)

Debt Instrument, Increase, Accrued Interest

$ 287,000

923,000

Debt Instrument, Interest Rate on Liability Component, Effective Percentage

9%

Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 69,700,000

69,700,000

Interest rate (as a percent)

4.25%

Debt Instrument Exchange Amount

55,300,000

Last Reported Sales Price Period, Common Stock

20 days

Debt Instrument, Convertible, Threshold Consecutive Trading Days

30

Percent of the Applicable Conversion Price

130%

Business Day Period

5 days

Debt Instrument, Convertible, Threshold Trading Days

10

Percent of the Product of the Last Reported Sale Price, Common Shares

98%

Convertible Senior Notes, Percentage of Principal Required for Repurchase

100%

Convertible Preferred Stock, Shares Issued upon Conversion | shares

94.6096

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 10.57

Debt Instrument, Net Carrying Amount

$ 69,700,000

67,665,000

Debt Instrument, Fee Amount

0

(2,035,000)

Debt Instrument, Increase, Accrued Interest

$ 247,000

$ 1,328,000

Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026

Debt Instrument [Line Items]

Debt Instrument, Face Amount

41,475,000

Debt Instrument, Convertible, Threshold Consecutive Trading Days | d

30

Debt Instrument, Fee Amount

$ (2,715,000)

(2,788,000)

Debt Instrument, Unamortized Discount

(1,356,000)

(1,447,000)

Debt Instrument, Non-Cash Interest Expense Recognized in the Period

$ 91,000

Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 125,000,000

Interest rate (as a percent)

4.25%

Long-term debt

$ 69,700,000

67,665,000

Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]

Debt Instrument [Line Items]

Business Day Period

5 years

Long-term debt

$ 77,758,000

76,719,000

Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 120,000,000

Interest rate (as a percent)

4.50%

Debt Instrument Exchange Amount

$ 38,500,000

Debt Instrument Repurchase Amount, Cash Paid

$ 2,650,000

Derivative, Price Risk Option Strike Price | $ / shares

$ 21.4375

Issuance of warrants

$ 14,100,000

Class of Warrant or Right, Outstanding | shares

1,113,854

Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Convertible, Threshold Trading Days

10

Long-term debt

$ 72,909,000

72,408,000

Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain]

Debt Instrument [Line Items]

Interest rate (as a percent)

5.68%

Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 - July 26, 2022 Issuance [Domain]

Debt Instrument [Line Items]

Debt Instrument, Fee Amount

$ 3,099,000

Debt Instrument, Increase, Accrued Interest

$ 589,000

Debt Instrument, Interest Rate on Liability Component, Effective Percentage

8.60%

Long-term debt

$ 37,404,000

37,240,000

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026

Debt Instrument [Line Items]

Interest rate (as a percent)

5.68%

Last Reported Sales Price Period, Common Stock

20 days

Percent of the Applicable Conversion Price

150%

Convertible Senior Notes, Percentage of Principal Required for Repurchase

100%

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Common Shares Exchanged | shares

2,700,000

Convertible Senior Notes, Holders Aggregate Principal Minimum requirement percentage, in the event of default

25%

Convertible Senior Notes, Additional Accrued interest in the Event of Failure to File Requirements under SEC Act of 1934

0.50%

Convertible Senior Notes, Additional Accrued interest in the Event of restrictive legends not being removed as of the 380th day after date of original issuance

0.50%

Debt Instrument, Percent limit on issuing common shares upon Conversion of the New 2026 Notes

19.99%

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | First year of loan period

Debt Instrument [Line Items]

Debt Instrument, Prepayment Premium, Percentage of aggregate principal amount

100%

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | Year 2 and on

Debt Instrument [Line Items]

Debt Instrument, Prepayment Premium, Percentage of aggregate principal amount

1%

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | Year 2 and on | Subsequent Event

Debt Instrument [Line Items]

Debt Instrument, Additional Prepayment Premium, Percentage of aggregate principal amount

3%

Secured Debt | Secured Term Loans due July 2026 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Fee Amount

$ 6,480,000

Debt Instrument, Face Amount

$ 55,500,000

90,500,000

104,500,000

Debt Instrument, Fee Amount

(3,471,000)

(5,846,000)

Debt Instrument, Unamortized Discount

(1,075,000)

(1,846,000)

Debt Instrument, Non-Cash Interest Expense Recognized in the Period

420,000

Debt Instrument, Increase, Accrued Interest

$ 2,225,000

Debt instrument, Springing Maturity Date

91 days

Debt Instrument, Debt Default, Amount

20,000,000

Debt Instrument, Interest Rate on Liability Component, Effective Percentage

14.90%

Long-term debt

$ 50,954,000

82,808,000

Secured Debt | Secured Term Loans due July 2026 [Domain] | Initial amount at closing [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

66,500,000

Secured Debt | Secured Term Loans due July 2026 [Domain] | Additional amount after closing (round 2) [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

8,500,000

Secured Debt | Secured Term Loans due July 2026 [Domain] | Additional amount after closing (round 3) [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

10,000,000

Secured Debt | Secured Term Loans due July 2026 [Domain] | Additional amount after closing (round 4) [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 14,000,000

$ 19,500,000

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain]

Debt Instrument [Line Items]

Interest rate (as a percent)

5.68%

Convertible Preferred Stock, Shares Issued upon Conversion | shares

333.3333

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 3

Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche II Notes [Domain]

Debt Instrument [Line Items]

Convertible Preferred Stock, Shares Issued upon Conversion | shares

222.222

Convertible Debt, Conversion Rate of Commmon Shares, Principal

$ 1,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 4.50

Secured Term Loan - issuance July 26th, 2022 [Domain] | Secured Term Loans due July 2026 [Domain]

Debt Instrument [Line Items]

Long-term debt

$ 82,808,000

Revolving Credit Facility | Line of Credit

Debt Instrument [Line Items]

Weighted average interest rate (as a percent)

9.50%

5.30%

Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)

Debt Instrument [Line Items]

Line of Credit Facility, Fair Value of Amount Outstanding

$ 15,220,000

Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)

Debt Instrument [Line Items]

Borrowing capacity

$ 35,000,000

Minimum availability reserve

$ 3,000,000

Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024

191 days

Debt Instrument, Springing Maturity, days prior to maturity of secured term loans due 2026

100 days

Letter of Credit

Debt Instrument [Line Items]

Line of Credit Facility, Fair Value of Amount Outstanding

$ 3,187,000

3,654,000

Letters of Credit Outstanding, Amount

$ 3,249,000

$ 4,229,000

Base Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | First year of loan period

Debt Instrument [Line Items]

Basis spread on variable rate

6%

Base Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | Year 2 and on

Debt Instrument [Line Items]

Basis spread on variable rate

7.75%

Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | First year of loan period

Debt Instrument [Line Items]

Basis spread on variable rate

7%

Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | Year 2 and on

Debt Instrument [Line Items]

Basis spread on variable rate

8.75%

Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)

Debt Instrument [Line Items]

Basis spread on variable rate

3.25%

Prime Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)

Debt Instrument [Line Items]

Basis spread on variable rate

2.25%

Long-Term Debt Sale Leaseback T

Long-Term Debt Sale Leaseback Transactions (Details)	Apr. 23, 2015 USD ($)
Sale Leaseback Transactions [Abstract]
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000

Other Long-Term Obligations (De

Other Long-Term Obligations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Apr. 23, 2015
Other Liabilities Disclosure [Abstract]
Deferred income taxes	$ 19,139,000		$ 18,771,000
Product liability	11,023,000		10,438,000
Pension	1,055,000		1,019,000
Deferred compensation	4,914,000		4,970,000
Deferred gain on sale leaseback, Net	4,747,000		4,834,000
Supplemental executive retirement plan liability	4,413,000		4,383,000
Death benefit obligation plan	2,616,000		2,533,000
Uncertain tax obligation including interest	2,918,000		2,891,000
Other	388,000		478,000
Other Long-Term Obligations, prior to reclassification to Liabilities subject to compromise	51,213,000		50,402,000
Other Long-Term Obligations	29,650,000		50,402,000
Sale Leaseback Transaction, Deferred Gain, Gross				$ 7,414,000
Sale and Leaseback Transaction, Gain (Loss), Net	84,000	$ 81,000
Convertible Debt Derivative	0		85,000
Liabilities Subject to Compromise, Other Liabilities	$ 21,563,000		$ 0

Leases and Commitments (Details

Leases and Commitments (Details) - USD ($)		3 Months Ended
	Apr. 23, 2015	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2020	Mar. 31, 2016	Jul. 01, 2020
Lessee, Lease, Description [Line Items]
Sale Leaseback Transaction, Lease Term		20 years
Sale and Leaseback Transaction, Gain (Loss), Net		$ 84,000	$ 81,000
Sale Leaseback Transaction, Annual Payments		$ 2,275,000
Lessee, Finance Lease, Term of Contract						19 years 9 months
Lease Obligation Incurred				$ 38,704,000
Sale Leaseback Transaction, Net Proceeds, Investing Activities					$ 23,000,000
Sale Leaseback Transaction, Lease Terms		Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then-current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases.
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000
Sale Leaseback Transaction, Immediate Loss Recognized	257,000
Capital Lease Obligations	$ 32,339,000
Minimum
Lessee, Lease, Description [Line Items]
General Lease Term		1 year
Maximum
Lessee, Lease, Description [Line Items]
General Lease Term		20 years

Leases and Commitments Lease Ex

Leases and Commitments Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating Lease, Expense	$ 1,548	$ 1,610
Short-term Lease, Cost	610	714
Operating Lease, Cost	2,158	2,324
Finance Lease, Interest Expense	1,067	1,083
Finance Lease, Right-of-Use Asset, Amortization	1,067	1,092
Financing Lease, Cost	$ 2,134	$ 2,175

Leases and Commitments Future M

Leases and Commitments Future Minimum Operating and Financing Lease Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Finance Lease, Liability, Payments, Due Next Twelve Months	$ 5,151
2023	3,689
Finance Lease, Liability, Payments, Due Year Two	6,808
2024	3,894
Finance Lease, Liability, Payments, Due Year Three	6,710
Finance Lease, Liability, Payments, Due Year Four	6,599
Finance Lease, Liability, Payments, Due Year Five	6,485
2027	392
Finance Lease, Liability, Payments, Due after Year Five	63,035
Thereafter	1,356
Finance Lease, Liability, Payments, Due	94,788
Total future minimum lease payments	13,094
Financing Leases, Future Minimum Payments, Interest Included in Payments	(33,818)
Operating Leases, Future Minimum Payments, Interest Included in Payments	(996)
Financing Leases, Future Minimum Payments, Present Value of Net Minimum Payments	60,970
Operating Leases, Future Minimum Payments, Present Value of Net Minimum Payments	12,098
Operating lease liability current prior to liabilities subject to compromise	4,142
Finance lease liability current prior to liabilities subject to compromise	3,162
Long-term operating lease obligations prior to liabilities subject to compromise	7,956
Finance Lease, Liability, Current	(3,162)	$ (3,106)
Operating Lease, Liability, Current	(4,142)	(3,420)
Financing Lease Liability, non-current	57,808
Operating Leases Long-Term Obligations	7,956	7,259
2025	2,539
2026	1,224
Finance Lease Long-Term Obligations	$ 57,808	$ 57,994

Leases and Commitments Suppleme

Leases and Commitments Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	$ 1,528	$ 2,239
Financing Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	1,843	1,829
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2,631	716
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	5	175
Right-of-Use Asset Obtained in Exchange for Total Lease Liability	2,636	891
Total Cash Paid in Measurement of Amounts for Lease Liabilities	$ 3,371	$ 4,068

Leases and Commitments Weighted

Leases and Commitments Weighted-Average Remaining Lease Terms and Discount Rates (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Finance Lease, Weighted Average Remaining Lease Term	14 years 6 months	14 years 9 months 18 days
Operating Lease, Weighted Average Remaining Lease Term	4 years 1 month 6 days	4 years 7 months 6 days
Finance Lease, Weighted Average Discount Rate, Percent	3.74%	3.74%
Operating Lease, Weighted Average Discount Rate, Percent	15.36%	9.36%

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 165,481,000	$ 200,988,000
Net Revenue	100%	100%
Deferred Revenue	$ 1,507,000		$ 2,279,000
Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 160,656,000	$ 196,830,000
Net Revenue	97%	98%
Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 4,825,000	$ 4,158,000
Net Revenue	3%	2%
Europe (EMEA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 104,923,000	$ 118,079,000
Europe (EMEA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	101,874,000	115,265,000
Europe (EMEA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	3,049,000	2,814,000
North America (NA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	52,364,000	75,319,000
North America (NA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	51,906,000	75,183,000
North America (NA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	458,000	136,000
All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	8,194,000	7,590,000
All Other | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	6,876,000	6,382,000
All Other | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 1,318,000	$ 1,208,000
General Terms and Conditions
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	25%
Large National Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	20%
Government Tenders
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	23%
Other Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split	32%

Equity Compensation (Narrative)

Equity Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2023 USD ($) votes $ / shares shares	Mar. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Description		The 2018 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any common shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each common share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share.
Allocated Share-based Compensation Expense | $		$ (54)	$ (345)
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $		$ 181	310
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period		3 years
Performance achievement level, lower range		0%
Performance achievement level, upper range		150%
Performance achievement level, target range		100%
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $		$ (54)	$ (345)
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares	[1]	5,329,514
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Share Awards Underlying from 2003 Plan | shares		1,466,569
Weighted Average | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition of unrecognized compensation costs		3 years
Class B Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Number of Votes | votes		10
Common Stock, Shares, Issued | shares		3,667
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Holders Percentage of Total Outstanding		99.90%
[1] *    Shares available for grant under the 2018 Plan as of March 31, 2023 are reduced by awards and increased by forfeitures or expirations. At March 31, 2023, an aggregate of 1,466,569 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.

Equity Compensation Share-based

Equity Compensation Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ (54)	$ (345)
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	181	310
Restricted Stock and Restricted Stock Units (RSUs) | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	235	655
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ (54)	$ (345)

Equity Compensation Unrecognize

Equity Compensation Unrecognized Compensation Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,838
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	2
Restricted Stock and Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,836

Equity Compensation (Options Ac

Equity Compensation (Options Activity) (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period (in shares) | shares	189,689
Options outstanding at end of period (in shares) | shares	86,227
Weighted Average Exercise Price
Options outstanding at beginning of period - Weighted Average Exercise Price (in dollars per share)	$ 13.43
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	$ 12.15
Options exercisable at end of period (in shares) | shares	86,227
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | shares	(103,462)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 14.49
Stock Options
Weighted Average Exercise Price
Options available for grant at end of period (in shares) | shares	5,329,514	[1]
$12.15 – $20.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share)	$ 12.15
$12.15 – $20.00 | Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	12.15
Range of Exercise Price Max [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per share)	$ 12.15
[1] *    Shares available for grant under the 2018 Plan as of March 31, 2023 are reduced by awards and increased by forfeitures or expirations. At March 31, 2023, an aggregate of 1,466,569 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.

Equity Compensation (Stock Opti

Equity Compensation (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 12.15	$ 13.43
$12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per share)	12.15
$12.15 – $20.00 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	12.15
$12.15 – $20.00 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	$ 20
Stock Options | $12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	86,227
Options Outstanding - Weighted Average Remaining Contractual Life	3 years 11 months 15 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 12.15
Options Exercisable - Number Exercisable At end of period (in shares)	86,227
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 12.15

Equity Compensation Restricted

Equity Compensation Restricted Stock Activity (Details) - Restricted Stock and Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance | shares	1,061,867
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	(23,601)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | shares	1,038,266
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.75
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	3.35
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.73

Equity Compensation Performance

Equity Compensation Performance Share Activity (Details) - Performance Shares - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	318,071	318,071
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 5.15	$ 5.15

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) by Component (Changes in Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	$ (24,723)	$ 16,988
OCI before reclassifications	5,643	(5,149)
Amount reclassified from accumulated OCI	200	(145)
Other Comprehensive Income (Loss)	5,843	(5,294)
Ending Balance	(18,880)	11,694
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(23,879)	18,961
OCI before reclassifications	6,283	(6,768)
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	6,283	(6,768)
Ending Balance	(17,596)	12,193
Accumulated Long-Term Notes Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(3,230)	2,127
OCI before reclassifications	(470)	426
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	(470)	426
Ending Balance	(3,700)	2,553
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	2,386	(4,101)
OCI before reclassifications	(77)	318
Amount reclassified from accumulated OCI	107	(94)
Other Comprehensive Income (Loss)	30	224
Ending Balance	2,416	(3,877)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	0	1
OCI before reclassifications	(93)	875
Amount reclassified from accumulated OCI	93	(51)
Other Comprehensive Income (Loss)	0	824
Ending Balance	$ 0	$ 825

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) by Component (Reclassified Out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	$ 121,637	$ 153,259
Amortization of prior service costs and unrecognized gains	53,809	60,564
Income tax provision	(940)	(1,320)
Net Sales	165,481	200,988
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of prior service costs and unrecognized gains	(107)	(94)
Income tax provision	0	0
Net loss from Continuing Operations	107	(94)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (Loss) from Continuing Operations before Income Taxes	133	(58)
Income tax provision	(40)	7
Net loss from Continuing Operations	93	(51)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	(133)	(31)
Net Sales	$ 0	$ (27)

Charges Related To Restructur_3

Charges Related To Restructuring Activities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 7,991,000
Charges	4,694,000	$ 4,694,000	$ 3,790,000
Payments	(10,706,000)	(10,706,000)	(1,336,000)
Ending Balance		1,979,000
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	3,472,000
Charges		135,000
Payments		(1,628,000)
Ending Balance		1,979,000
Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	654,000
Payments	(654,000)
Ending Balance	0
Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	4,519,000
Charges		3,905,000
Payments		(8,424,000)
Ending Balance		0
North America (NA)
Restructuring Reserve [Roll Forward]
Beginning Balance	3,993,000
Charges	3,722,000	3,722,000	1,662,000
Restructuring Reserve, Accrual Adjustment	3,722,000
Payments		(7,282,000)
Ending Balance		433,000
North America (NA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	967,000
Charges		57,000	1,662,000
Payments		(591,000)
Ending Balance		433,000
North America (NA) | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Restructuring Reserve, Accrual Adjustment	0
Payments	0
Ending Balance	0
North America (NA) | Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	3,026,000
Charges		3,665,000
Payments		6,691,000
Ending Balance		0
Europe (EMEA)
Restructuring Reserve [Roll Forward]
Beginning Balance	2,807,000
Charges	972,000	972,000	2,119,000
Payments		(3,236,000)
Ending Balance		543,000
Europe (EMEA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	1,314,000
Charges		78,000
Payments		(849,000)
Ending Balance		543,000
Europe (EMEA) | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	654,000
Payments	(654,000)
Ending Balance	0
Europe (EMEA) | Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	1,493,000
Charges		240,000
Payments		1,733,000
Ending Balance		0
All Other
Restructuring Reserve [Roll Forward]
Beginning Balance	1,191,000
Charges	0	0	$ 9,000
Payments		(188,000)
Ending Balance	1,003,000
All Other | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	1,191,000
Charges		0
Payments		(188,000)
Ending Balance	1,003,000
All Other | Contract Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	0
Payments	0
Ending Balance	$ 0
All Other | Other Restructuring
Restructuring Reserve [Roll Forward]
Charges		0
Payments		$ 0

Charges Related To Restructur_4

Charges Related To Restructuring Activities Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]
Charges	$ 4,694,000	$ 4,694,000	$ 3,790,000
Restructuring and Related Activities, Expected Payout Period	12 months
Payments	$ (10,706,000)	(10,706,000)	(1,336,000)
Severance
Restructuring Cost and Reserve [Line Items]
Charges		135,000
Payments		(1,628,000)
Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	654,000
Payments	(654,000)
North America (NA)
Restructuring Cost and Reserve [Line Items]
Charges	3,722,000	3,722,000	1,662,000
Restructuring Reserve, Accrual Adjustment	3,722,000
Payments		(7,282,000)
North America (NA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges		57,000	1,662,000
Payments		(591,000)
North America (NA) | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0
Payments	0
Europe (EMEA)
Restructuring Cost and Reserve [Line Items]
Charges	972,000	972,000	2,119,000
Payments		(3,236,000)
Europe (EMEA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges		78,000
Payments		(849,000)
Europe (EMEA) | Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	654,000
Payments	(654,000)
All Other
Restructuring Cost and Reserve [Line Items]
Charges	0	0	$ 9,000
Payments		(188,000)
All Other | Severance
Restructuring Cost and Reserve [Line Items]
Charges		0
Payments		$ (188,000)
All Other | Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges	0
Payments	$ 0

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Valuation Allowance [Line Items]
Effective income tax rate, continuing operations	(2.30%)	(5.80%)
U.S. statutory income tax rate	21%
Effective income tax rate, continuing operations	(2.30%)	(5.80%)
U.S. statutory income tax rate	21%

Net Earnings (Loss) Per Commo_3

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Net Loss per Share—Basic
Average common shares outstanding		37,994	35,046
Net Loss		$ (41,177)	$ (24,197)
Net earnings (loss) per common share		$ (1.08)	$ (0.69)
Net Loss per Share—Assuming Dilution
Average common shares outstanding		37,994	35,046
Stock options and awards		43	373
Average common shares assuming dilution		38,037	35,419
Net Loss		$ (41,177)	$ (24,197)
Net earnings (loss) per per common share—assuming dilution (in dollars per share)	[1]	$ (1.08)	$ (0.69)
[1]Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Net Earnings (Loss) Per Commo_4

Net Earnings (Loss) Per Common Share Textuals (Details) - Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,246,025	1,861,644
Antidilutive share granted, average exercise price	$ 12.15	$ 12.15
Fair value stock price	$ 0.23	$ 2.14

Concentration Of Credit Risk (D

Concentration Of Credit Risk (Details)	Mar. 31, 2023 USD ($)
Risks and Uncertainties [Abstract]
Retained Recourse Obligation For Events Of Default Under Contracts	$ 2,113,000
Events of Default Under Contract by Third Party	$ 6,941,000

Derivatives Notional Amounts -

Derivatives Notional Amounts - Designated as Hedges (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Dec. 31, 2022
Derivative [Line Items]
Notional Amount	$ 0		$ 60,964
Gain (Loss)	$ 0	$ 980

Derivatives Notional Amounts _2

Derivatives Notional Amounts - Not Designated as Hedges (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2022
Derivative [Line Items]
Notional Amount	$ 0			$ 60,964
Gain (Loss)	0		$ 980
Forward exchange contracts—net
Derivative [Line Items]
Gain (Loss)		$ 602
EUR / USD
Derivative [Line Items]
Notional Amount	0			$ 60,964
Gain (Loss)	$ 0		$ 980

Derivatives Balance Sheet Locat

Derivatives Balance Sheet Location (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Current Assets
Derivatives, Fair Value [Line Items]
Derivative assets	$ 0	$ 1,117
Other Current Assets | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative assets	0	1,117
Accrued Expenses
Derivatives, Fair Value [Line Items]
Derivative liabilities	0	137
Accrued Expenses | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 0	$ 137

Derivatives Gain (Loss) in Stat

Derivatives Gain (Loss) in Statement of Finacial Position (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)	$ 133,000	$ (58,000)
Foreign currency forward contracts | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	(93,000)	875,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(93,000)	51,000
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	0
Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)	$ 0		$ 980,000
Not Designated as Hedging Instrument [Member] | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)		$ 602,000

Derivatives Narrative (Details)

Derivatives Narrative (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2017	Dec. 31, 2022
Derivative [Line Items]
Convertible Debt Derivative	$ 0			$ 85,000
Debt Instrument, Convertible, Beneficial Conversion Feature				1,595,000
Net gain on convertible debt derivatives	85,000	$ 0
Foreign currency forward contracts
Derivative [Line Items]
Notional amount of derivatives, matured during period	$ 6,720,000	10,666,000
Minimum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure	50%
Maximum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure	90%
Cash Flow Hedging [Member]
Derivative [Line Items]
Gain (Loss)	$ (133,000)	58,000
Cash Flow Hedging [Member] | Sales [Member]
Derivative [Line Items]
Gain (Loss)	0	(27,000)
Cash Flow Hedging [Member] | Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss)	$ (133,000)	$ (31,000)
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Derivative [Line Items]
Proceeds from Issuance of Warrants			$ 14,100,000
Debt Instrument, Face Amount			$ 120,000,000
Interest rate (as a percent)	4.50%
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Derivative [Line Items]
Debt Instrument, Face Amount				$ 41,475,000

Fair Values (Assets and Liabili

Fair Values (Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	$ (393,264)	$ (354,241)
Convertible Subordinated Debt | Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	$ 0	(85)
Forward exchange contracts—net | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net		0
Forward exchange contracts—net | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net		980
Forward exchange contracts—net | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net		0
Convertible Debt Derivative | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net		$ (85)

Fair Values (Details of Book Va

Fair Values (Details of Book Value and Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents		$ 58,792	$ 52,337	$ 83,745
Cash and cash equivalents	$ 66,284	58,792
Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	66,284	58,792
Debt Instrument, Fair Value Disclosure	(170,940)	(278,027)
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	66,284
Cash and cash equivalents		58,792
Debt Instrument, Fair Value Disclosure	(393,264)	(354,241)
Convertible Senior Notes at 5.00% November 2024 | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(3,645)	(62,460)
Convertible Senior Notes at 5.00% November 2024 | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(72,909)	(72,408)
Series II Convertible Senior Notes at 5.00% November 2024 | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(3,888)	(64,678)
Series II Convertible Senior Notes at 5.00% November 2024 | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(77,758)	(76,719)
Other Notes and Capital Lease Obligations | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(16,040)	(17,401)
Other Notes and Capital Lease Obligations | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(16,040)	(17,401)
Convertible Senior Notes at 4.25% March 2026 | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(3,485)	(32,276)
Convertible Senior Notes at 4.25% March 2026 | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(69,700)	(67,665)
Convertible Senior Secured Notes at 5.68% July 2026 - July 26, 2022 Issuance [Domain] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(27,529)	(34,341)
Convertible Senior Secured Notes at 5.68% July 2026 - July 26, 2022 Issuance [Domain] | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(37,404)	(37,240)
Secured Term Loans due July 2026 [Domain] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(47,854)	(66,871)
Secured Term Loans due July 2026 [Domain] | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(50,954)	(82,808)
Convertible Subordinated Debt | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(85)
Convertible Subordinated Debt | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(85)
Debtor in Possession (DIP) Term Loan | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(68,499)	0
Debtor in Possession (DIP) Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ (68,499)	$ 0
Foreign currency forward contracts | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Foreign currency forward contracts | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets

Business Segments (Information

Business Segments (Information by Segment) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net Sales	$ 165,481,000		$ 200,988,000
Restructuring Reserve		$ 1,979,000		$ 7,991,000
Charges	(4,694,000)	(4,694,000)	(3,790,000)
Net gain on sale of businesses	4,212,000		0
Operating Loss	(10,447,000)		(16,625,000)
Interest Revenue (Expense), Net	(9,084,000)		(6,252,000)
Earnings (loss) before income taxes	(40,237,000)		(22,877,000)
Net gain on convertible debt derivatives	85,000		0
Reorganization Items	(20,791,000)		0
Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	104,923,000		118,079,000
Restructuring Reserve		543,000		2,807,000
Charges	(972,000)	(972,000)	(2,119,000)
Operating Loss	6,170,000		3,225,000
North America (NA)
Segment Reporting Information [Line Items]
Net Sales	52,364,000		75,319,000
Restructuring Reserve		433,000		3,993,000
Restructuring Reserve, Accrual Adjustment	3,722,000
Charges	(3,722,000)	(3,722,000)	(1,662,000)
Operating Loss	(10,315,000)		(8,336,000)
All Other
Segment Reporting Information [Line Items]
Net Sales	8,194,000		7,590,000
Restructuring Reserve	1,003,000			1,191,000
Charges	0	0	(9,000)
Operating Loss	(5,820,000)		(7,724,000)
Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	104,923,000		118,079,000
Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	52,364,000		75,319,000
Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	8,194,000		7,590,000
Intersegment revenues
Segment Reporting Information [Line Items]
Net Sales	11,283,000		15,531,000
Intersegment revenues | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,431,000		4,435,000
Intersegment revenues | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	6,842,000		11,096,000
Intersegment revenues | All Other
Segment Reporting Information [Line Items]
Net Sales	10,000		0
Severance
Segment Reporting Information [Line Items]
Restructuring Reserve		1,979,000		3,472,000
Charges		(135,000)
Severance | Europe (EMEA)
Segment Reporting Information [Line Items]
Restructuring Reserve		543,000		1,314,000
Charges		(78,000)
Severance | North America (NA)
Segment Reporting Information [Line Items]
Restructuring Reserve		433,000		967,000
Charges		(57,000)	(1,662,000)
Severance | All Other
Segment Reporting Information [Line Items]
Restructuring Reserve	1,003,000			1,191,000
Charges		$ 0
Contract Termination
Segment Reporting Information [Line Items]
Restructuring Reserve	0			0
Charges	(654,000)
Contract Termination | Europe (EMEA)
Segment Reporting Information [Line Items]
Restructuring Reserve	0			0
Charges	(654,000)
Contract Termination | North America (NA)
Segment Reporting Information [Line Items]
Restructuring Reserve	0			0
Restructuring Reserve, Accrual Adjustment	0
Contract Termination | All Other
Segment Reporting Information [Line Items]
Restructuring Reserve	0			$ 0
Charges	0
Lifestyle Products [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	52,802,000		61,064,000
Lifestyle Products [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	28,049,000		34,301,000
Lifestyle Products [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	2,758,000		2,826,000
Mobility and Seating [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	42,916,000		47,402,000
Mobility and Seating [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	22,312,000		25,422,000
Mobility and Seating [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	2,384,000		2,690,000
Respiratory Therapy [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,692,000		4,663,000
Respiratory Therapy [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	1,545,000		15,460,000
Respiratory Therapy [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	1,639,000		779,000
Other [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,513,000		4,950,000
Other [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	458,000		136,000
Other [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	$ 1,413,000		$ 1,295,000

Contingencies Contingencies (De

Contingencies Contingencies (Details)	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Liquidated Damages amount per violation per day	$ 15,000
Liquidated Damages - Yearly Limit	$ 7,000,000

Reorganizations (Details)

Reorganizations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Liabilities Subject to Compromise, Accounts Payable and Accrued Liabilities	$ 26,948,000
Liabilities subject to compromise, accrued expenses	18,748,000			$ 0
Liabilities subject to compromise, total current liabilities	45,696,000
Liabilities subject to compromise, long term debt	220,367,000
Liabilities Subject to Compromise, Other Liabilities	21,563,000			0
Liabilities Subject to Compromise	287,626,000			0
Debtor Reorganization Items, Legal and Advisory Professional Fees	13,598,000
Debtor Reorganization Items, Debtor-in-Possession Facility Financing Costs	5,474,000
Debtor Reorganization Items, Write-off of Debt Issuance Costs and Debt Discounts	4,060,000
Debtor Reorganization Items, Gain (Loss) on Settlement of Other Claims, Net	(2,341,000)
Reorganization Items	20,791,000		$ 0
Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023)	9,101,000		6,252,000
Cash paid for reorganization items	4,021,000
Cash paid DIP financing costs	3,664,000
Cash paid professional fees	357,000
Valuation reserve associated with defined benefit plan activity	5,000		47,000
Gross Profit	43,844,000		47,729,000
Equity in earnings of non-debtor entities	(7,057,000)
Deferred tax adjustment resulting from defined benefit plan activity	(5,000)		(47,000)
Cash and cash equivalents	66,284,000			58,792,000
Trade receivables, net	82,659,000			87,952,000
Inventories, net	103,635,000			112,561,000
Other current assets	32,947,000			39,702,000
Assets, Current	285,788,000			299,318,000
Other Assets	4,610,000			5,159,000
Intangibles, net	21,771,000			21,669,000
Property and Equipment, net	50,514,000			51,533,000
Finance Lease, Right-of-Use Asset	55,809,000			56,272,000
Operating Lease, Right-of-Use Asset	12,111,000			10,737,000
Assets	762,116,000			770,969,000
Net Loss	(41,177,000)		(24,197,000)
Accounts payable	72,588,000			104,590,000
Accrued expenses	77,712,000			106,091,000
Current taxes payable	2,636,000			2,774,000
Current portion of long-term debt	35,656,000			154,000
Current portion of finance lease obligations	3,162,000			3,106,000
Current portion of operating lease obligations	4,142,000			3,420,000
Liabilities, Current	195,896,000			220,135,000
Long-Term Debt	137,241,000			354,087,000
Finance Lease Long-Term Obligations	57,808,000			57,994,000
Operating Leases Long-Term Obligations	7,956,000			7,259,000
Other Long-Term Obligations	29,650,000			50,402,000
Liabilities and Equity	762,116,000			770,969,000
Net Sales	165,481,000		200,988,000
Cost of products sold	121,637,000		153,259,000
Selling, general and administrative expenses	53,809,000		60,564,000
Net gain on sale of businesses	(4,212,000)		0
Charges	4,694,000	$ 4,694,000	3,790,000
Operating Loss	(10,447,000)		(16,625,000)
Net gain on convertible debt derivatives	85,000		0
Earnings (loss) before income taxes	(40,237,000)		(22,877,000)
Income tax provision	940,000		1,320,000
Amortization of prior service costs and unrecognized losses	30,000		224,000
Other Comprehensive Income (Loss), Net of Tax	5,843,000		(5,294,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(35,334,000)		(29,491,000)
Depreciation and amortization	3,570,000		3,942,000
Amortization of operating lease right of use assets	1,226,000		1,375,000
Provision for Doubtful Accounts	24,000		96,000
Other Noncash Expense	169,000		44,000
Provision for equity compensation	181,000		310,000
Gain (Loss) on Disposition of Property Plant Equipment	(87,000)		(34,000)
Noncash reorganization items net	5,464,000		0
Convertible Debt Discount Amortization and Accretion	960,000		911,000
Amortization of debt fees	1,817,000		615,000
Other Noncash Income	184,000		0
Increase (Decrease) in Inventories	2,980,000		(3,615,000)
Increase (Decrease) in Other Operating Assets	6,976,000		(3,361,000)
Accounts payable	(3,201,000)		(8,323,000)
Accrued expenses	(10,765,000)		(4,372,000)
Other long-term liabilities	(315,000)		(1,824,000)
Net Cash Provided by (Used in) Operating Activities	(30,614,000)		27,698,000
Increase (Decrease) in Accounts Receivable	5,605,000		10,481,000
Proceeds from sale of businesses	11,596,000		0
Payments for (Proceeds from) Long-Term Investments	2,000		(91,000)
Payments for (Proceeds from) Other Investing Activities	(540,000)		4,000
Net Cash Provided by (Used in) Investing Activities	9,080,000		(2,213,000)
Proceeds from revolving lines of credit and long-term borrowings	43,042,000		3,484,000
Repayments of Long-Term Debt	(10,274,000)		(4,420,000)
Payment of financing costs (1)	(4,155,000)		(244,000)
Net Cash Provided by (Used in) Financing Activities	28,613,000		(1,180,000)
Effect of exchange rate changes on cash	413,000		(317,000)
Cash, Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	7,492,000		(31,408,000)
Cash and cash equivalents			52,337,000	58,792,000	$ 83,745,000
Payments to Acquire Property, Plant, and Equipment	(1,978,000)		$ (2,131,000)
Contractual Interest Expense on Prepetition Liabilities Not Recognized in Statement of Operations	$ 2,269,000
Condensed combined debtor-in-possession comprehensive income statement	INVACARE CORPORATION AND SUBSIDIARIES (Debtor-in-Possession) Condensed Combined Statement of Comprehensive Income (Loss) (unaudited) Debtors' Statements of Loss (In thousands, except per share data) Three Months Ended March 31, 2023 Net sales $ 41,678 Cost of products sold 36,937 Gross Profit 4,741 Selling, general and administrative expenses 23,481 Gain on sale of business (4,212) Charges related to restructuring activities 3,749 Operating Loss (18,277) Net gain on convertible debt derivatives (85) Reorganization items, net 20,791 Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023) 9,241 Equity in earnings of non-debtor entities (7,057) Loss Before Income Taxes (41,167) Income tax provision 10 Net Loss $ (41,177) Other comprehensive income (loss): Defined benefit plans: Amortization of prior service costs and unrecognized losses 23 Deferred tax adjustment resulting from defined benefit plan activity (5) Valuation reserve associated with defined benefit plan activity 5 Other Comprehensive Income (Loss) 23 Comprehensive Loss $ (41,154)
Reorganization, Chapter 11, Debtor-in-Possession
Reorganization, Chapter 11 [Line Items]
Liabilities Subject to Compromise	$ 287,626,000
Reorganization Items	20,791,000
Interest expense (excludes contractual interest of $2,269 for the three months ended March 31, 2023)	9,241,000
Valuation reserve associated with defined benefit plan activity	5,000
Gross Profit	4,741,000
Deferred tax adjustment resulting from defined benefit plan activity	(5,000)
Cash and cash equivalents	27,892,000
Trade receivables, net	18,595,000
Due from non-debtor affiliates	105,690,000
Inventories, net	28,171,000
Other current assets	10,664,000
Assets, Current	191,012,000
Other Assets	2,593,000
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity	515,759,000
Intangibles, net	2,415,000
Property and Equipment, net	29,754,000
Finance Lease, Right-of-Use Asset	20,259,000
Operating Lease, Right-of-Use Asset	324,000
Assets	762,116,000
Net Loss	(41,177,000)
Accounts payable	14,697,000
Due to non-debtor affiliates	117,233,000
Accrued expenses	30,481,000
Current taxes payable	758,000
Current portion of long-term debt	35,500,000
Current portion of finance lease obligations	1,642,000
Current portion of operating lease obligations	222,000
Liabilities, Current	200,533,000
Long-Term Debt	137,228,000
Finance Lease Long-Term Obligations	21,166,000
Operating Leases Long-Term Obligations	83,000
Other Long-Term Obligations	5,063,000
Total equity attributable to debtors	110,417,000
Liabilities and Equity	762,116,000
Net Sales	41,678,000
Cost of products sold	36,937,000
Selling, general and administrative expenses	23,481,000
Net gain on sale of businesses	(4,212,000)
Charges	3,749,000
Operating Loss	(18,277,000)
Net gain on convertible debt derivatives	85,000
Earnings (loss) before income taxes	(41,167,000)
Income tax provision	10,000
Amortization of prior service costs and unrecognized losses	23,000
Other Comprehensive Income (Loss), Net of Tax	23,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(41,154,000)
Depreciation and amortization	1,895,000
Amortization of operating lease right of use assets	199,000
Provision for Doubtful Accounts	23,000
Gain (Loss) on Disposition of Property Plant Equipment	(88,000)
Increase (Decrease) in Inventories	6,046,000
Increase (Decrease) in Other Operating Assets	(1,623,000)
Accounts payable	(2,254,000)
Accrued expenses	13,931,000
Other long-term liabilities	(945,000)
Net Cash Provided by (Used in) Operating Activities	(21,413,000)
Increase (Decrease) in Accounts Receivable	5,159,000
Payments for (Proceeds from) Long-Term Investments	(2,000)
Payments for (Proceeds from) Other Investing Activities	(540,000)
Net Cash Provided by (Used in) Investing Activities	11,000,000
Repayments of Long-Term Debt	(12,080,000)
Net Cash Provided by (Used in) Financing Activities	26,807,000
Effect of exchange rate changes on cash	0
Cash, Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	16,394,000
Cash and cash equivalents	27,892,000			$ 11,498,000
Payments to Acquire Property, Plant, and Equipment	$ (54,000)

Subsequent Events (Details)

Subsequent Events (Details)	2 Months Ended	3 Months Ended
	May 22, 2023 USD ($) d Rate	Mar. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	May 12, 2023 shares	May 05, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Jul. 26, 2022
Subsequent Event [Line Items]
Charges		$ 4,694,000	$ 4,694,000	$ 3,790,000
Entity Common Stock, Shares Outstanding | shares					9,999,980
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.25
Severance
Subsequent Event [Line Items]
Charges			$ 135,000
Contract Termination
Subsequent Event [Line Items]
Charges		$ 654,000
Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued | shares		42,518,000					42,540,000
Convertible Senior Secured Notes at 5.68% July 2026 | Convertible Subordinated Debt
Subsequent Event [Line Items]
Debt Instrument, Face Amount							$ 41,475,000
Convertible Senior Secured Notes at 5.68% July 2026 | Secured Debt
Subsequent Event [Line Items]
Interest rate (as a percent)								5.68%
Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain] | Convertible Subordinated Debt
Subsequent Event [Line Items]
Interest rate (as a percent)								5.68%
Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain] | Secured Debt
Subsequent Event [Line Items]
Interest rate (as a percent)								5.68%
Subsequent Event
Subsequent Event [Line Items]
Charges	$ 1,700,000
Restructuring and Related Cost, Number of Positions Eliminated | d	90
Payments for Legal Settlements	$ 2,000,000
Debt Instrument, Face Amount						$ 85,000,000
Subsequent Event | Severance
Subsequent Event [Line Items]
Charges	900,000
Subsequent Event | Contract Termination
Subsequent Event [Line Items]
Charges	$ 800,000
Subsequent Event | Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued | shares						9,999,980
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.001
Subsequent Event | Convertible Preferred Stock
Subsequent Event [Line Items]
Preferred Stock, Shares Issued | shares						6,750,011
Preferred Stock, Par or Stated Value Per Share | $ / shares						$ 0.001
Preferred Stock, Dividend Rate, Percentage | Rate	9%
Subsequent Event | Convertible Senior Secured Notes at 7.50% due 2028 - Tranche I
Subsequent Event [Line Items]
Interest rate (as a percent)						7.50%
Subsequent Event | Convertible Senior Secured Notes at 7.50% due 2028 - Tranche I | Convertible Subordinated Debt
Subsequent Event [Line Items]
Debt Instrument, Face Amount						$ 25,739,000
Subsequent Event | Convertible Senior Secured Notes at 7.50% due 2028 - Tranche II | Convertible Subordinated Debt
Subsequent Event [Line Items]
Debt Instrument, Face Amount						$ 20,736,000
Subsequent Event | Convertible Senior Secured Notes at 7.50% due 2028 - Tranche II | Secured Debt
Subsequent Event [Line Items]
Interest rate (as a percent)						7.50%